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ABSTRACT 
Parkinson’s disease (PD) is the second most common neurological disease, characterised by 
cardinal symptoms such as bradykinesia, resting tremors, muscle rigidity, postural instability and 
gait disturbances. In particular, deficits in lower limb function and gait significantly impact 
activities of daily living and quality of life. In this study, the effects of 2 modalities – progressive 
resistance training combined with balance-specific training (PRBT), and non-invasive 
transcranial direct current stimulation (tDCS), on measures of gait (i.e. single- and dual-task step 
length and velocity), corticospinal excitability and inhibition, clinical and functional outcome 
measures in people with moderate PD were investigated. 
A total of 33 participants with moderate PD (Hoehn & Yahr score 2-4) were randomised into 3 
groups that received either PRBT and anodal tDCS (Ex+tDCS), and PRBT and sham tDCS 
(Ex+Sham), or usual care (Control). Participants that were assigned to the experimental groups 
partook in 6 weeks (3 days a week) of one-on-one PRBT with an exercise physiologist, consisting 
of strength and gait training exercises in conjunction with either sham or anodal tDCS. The 
exercise physiologist was blinded to the randomisation of tDCS. Participants assigned to the 
Control group only attended the testing sessions, but were offered the training program after the 
trial. All outcome measures were tested at Baseline, mid-intervention (3 weeks), post-
intervention (6 weeks), and at follow up 3 weeks after the intervention (9 weeks). The primary 
outcome measure of this study was gait performance, specifically single- and dual- task step length 
and step velocity. The secondary outcome measures included peripheral muscle excitability, 
corticospinal excitability (motor-evoked potential [MEP] amplitude) and inhibition (short-
interval intracortical inhibition [SICI]) as measured using single- and paired- pulse transcranial 
magnetic stimulation (TMS) respectively, clinical and lower limb function 
measures such as the Movement Disorder Society Unified PD rating motor subscale III & IV 
(MDS-UPDRS-III & IV), timed up-and-go test (TUG), Berg Balance Scale (BBS), 5 times sit- 
to-stand test (FTSTST), and 1-repetition maximum (1RM) of the quadriceps, hamstring, 
gastrocnemius and tibialis anterior muscles. 
The results from this study showed that dual-task step velocity and dual-task velocity cost was 
significantly improved in the Ex+tDCS group compared to Baseline, Control and Ex+Sham 
groups at 3, 6 and 9 weeks. Further, a significant improvement in dual-task step length and dual-
task step length cost with the Ex+Sham group at 6 and 9 weeks compared to Baseline and Control 
group. However a greater improvement in dual-task step length and dual-task cost was observed 
in the Ex+tDCS group compared to Ex+Sham and Control groups. No significant differences 
were observed in single-task step length and velocity for all 3 groups. 
Apart from an improvement in gait performance, the results showed an increase in peripheral 
muscle excitability and reduced cortical inhibition in both experimental groups. Further, a 
significant increase in peripheral muscle excitability was observed at 3 and 9 weeks for both the 
Ex+Sham and Ex+tDCS groups compared to Control and Baseline. No differences were 
observed between Ex+Sham and Ex+tDCS groups. For measures of cortical inhibition, SICI was 
significantly reduced only at 9 weeks for the Ex+Sham group from Controls and Baseline, 
however, the Ex+tDCS group showed a greater reduction in SICI at both 6 and 9 weeks compared 
to Baseline, and both Ex+Sham and Control. No significant difference was observed in single-
pulse MEP amplitude across all groups and time points. 
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For clinical and lower limb functional measures, the results showed a significant improvement 
in MDS-UPDRS-III & IV score, and 1RM strength of the gastrocnemius muscle for both 
Ex+Sham and Ex+tDCS groups at 3, 6 and 9 weeks compared to the Control group. For the 
TUG, FTSTST, 1RM strength of the quadriceps and tibialis anterior muscles, a significant 
improvement was observed at 6 and 9 weeks in both the Ex+Sham and Ex+tDCS groups 
compared to the Control group. For all clinical and lower limb functional measures, no 
differences were observed between Ex+Sham and Ex+tDCS groups. 
Overall, the findings from this thesis showed that the use of PRBT is beneficial for eliciting 
improvements to gait performance by reducing dual-task cost in step length and velocity, 
cortical inhibition and clinical and function measures of the lower limb. When tDCS was 
combined with PRBT, the improvements in dual-task cost of step length and velocity and 
cortical inhibition was further improved. However, no further improvements were observed 
in clinical and lower limb functional measures. These findings suggest an improvement in 
central processing of dual-task gait associated with PRBT, and greater improvement in neural 
efficiency when anodal tDCS is applied during PRBT, which may be underpinned by 
modulations of inhibitory cortical circuits. 
For clinical and lower limb functional measures, the results showed a significant improvement 
in MDS-UPDRS-III & IV score, and 1RM strength of the gastrocnemius muscle for both 
Ex+Sham and Ex+tDCS groups at 3, 6 and 9 weeks compared to the Control group. For the 
TUG, FTSTST, 1RM strength of the quadriceps and tibialis anterior muscles, a significant 
improvement was observed at 6 and 9 weeks in both the Ex+Sham and Ex+tDCS groups 
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compared to the Control group. For all clinical and lower limb functional measures, no 
differences were observed between Ex+Sham and Ex+tDCS groups.   
Overall, the findings from this thesis showed that the use of PRBT is beneficial for eliciting 
improvements to gait performance by reducing dual-task cost in step length and velocity, 
cortical inhibition and clinical and function measures of the lower limb. When tDCS was 
combined with PRBT, the improvements in dual-task cost of step length and velocity and 
cortical inhibition was further improved. However, no further improvements were observed in 
clinical and lower limb functional measures. These findings suggest an improvement in central 
processing of dual-task gait associated with PRBT, and greater improvement in neural 
efficiency when anodal tDCS is applied during PRBT, which may be underpinned by 
modulations of inhibitory cortical circuits.  
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CHAPTER 1 INTRODUCTION 
1.1 Background 
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder caused by the 
depletion of the neurotransmitter dopamine (DA), which is produced by cells located in the 
zona compacta of the substantia nigra [1-4]. Early motor symptoms associated with PD can 
manifest as resting tremors, muscle stiffness in the lower and upper limbs, slowness in 
movements and postural imbalances [5, 6]. Furthermore, impairments to balance and gait 
function progressively worsens with time, and are resistant to common pharmaceutical 
treatments. This can dramatically impact on an individual’s mobility and quality-of-life [7, 8].  
 
Compared to other neurological disorders, one of the main risk factor associated with PD is the 
risk of falls [9]. In a healthy ageing population, the risk of falls have been linked to the loss of 
power [10], and the inability to generate maximal muscle strength [10-12]. Similarly, people 
with PD exhibit significant muscle weakness, and lower limb motor impairment (i.e. postural 
instability and gait dysfunction) [10, 13], which increases their prevalence of falls by 68% 
compared to healthy age-match adults [9, 14]. Further, dual tasking during active gait (i.e. 
walking and talking) has also showed to increase the risk of falls in people with PD [9].  Studies 
have further indicated that people with PD that have fallen two or more times in the span of 12 
months are 59% more likely to fall again, and among those people, 33% would have 
experienced serious injuries resulting in hospitalization [15-17].  As a result, interventions 
aimed to ameliorate neuromuscular and lower limb motor impairments (i.e. postural instability 
and gait dysfunction) for people with PD may be beneficial in improving activities of daily 
living and overall quality of life. 
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In recent years, exercise therapy has been accepted as a rehabilitation tool in various 
neurological populations [18, 19], and has received attention for the treatment of motor 
symptoms found in PD [20]. Through the use of regular exercise training (i.e. aerobic, 
resistance, high-intensity strength training), structural and functional neuromuscular 
improvements occur, which has been shown to attenuate declines in motor function in people 
with PD [21, 22]. In particular, progressive resistance training (PRT) can improve muscle 
strength [13, 23], gait initiation and gait speed [19, 23] in people with PD.  A study by Rafferty 
et al. [24] conducted a 2-year exercise intervention, which marginally improved gait velocity 
during fast movement testing, and showed a significant improvement in plantarflexion 
strength, which was associated with the improvement in gait velocity.  Furthermore, PRT in 
combination with other functional exercise modalities, such as balance-specific training (BT) 
and stretching, improved lower limb strength function [18, 25], decreased postural sway and 
reduced amount of falls [26], and improved quality of life [22, 26].  
 
There is evidence to suggest that PRT and functional skill training can also induce changes in 
the central nervous system (CNS) [27]. Referred to as ‘neuroplasticity,’ changes in the 
excitability of neural pathways is an intrinsic property that underpins the way the brain acquires 
new motor skills through learning or neuro-rehabilitation [28]. Specifically, the use of novel 
task-specific training (i.e. balance or functional training) [29, 30], in combination with PRT 
has been shown to induce greater levels of neuroplasticity [28, 31], compared to PRT and BT 
alone. In addition, a recent study by Sparrow et al. [32] demonstrated that a highly challenging 
balance program combined with exercise training, increased postural stability, muscle strength 
and functional performance in people with PD.  This may also indicate that both programs, 
when incorporated at high demands exhibit neuroplastic changes, presenting functional and 
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motor retention, resulting in recurrent neural firing to targeted muscle regions for functional 
control.  
 
Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique 
that has shown promising results as a complementary neuro-rehabilitation tool in PD [33].  
Transcranial direct current stimulation is a painless neuro-modulatory technique that involves 
passing low-intensity direct current (0.5 – 2 milliamps) into the brain to either excite or inhibit 
neural function [34, 35]. In particular, the application of low-intensity direct current using a 
positive (anode) and negative (cathode) surface electrode over the primary motor cortex (M1) 
has been shown to increase or decrease corticospinal excitability, respectively [34, 36]. Of 
interest, when used as a standalone treatment or in conjunction with other therapies, studies 
have shown that the application of anodal tDCS (a-tDCS) can improve the performance of 
functional motor tasks such as those pertaining to balance and gait [37, 38]. A study by 
Goodwill et al. [39] demonstrated how task-specific training in combination with a-tDCS 
showed a 13 - 21% improvement in motor function and mobility in healthy aged adults 
compared to task-specific training alone. This suggests that the effects of a-tDCS, with the 
additional activity of task-specific training, induced spontaneous neuronal firing in the M1, 
which expedited the performance and learning of a motor task. To date, progressive resistance 
in combination with balance-specific training (PRBT) and a-tDCS have not been explored in 
people with PD. It is currently not known if the addition of a-tDCS during PRBT will further 
augment corticospinal excitability in people with PD and improve balance and gait function, 
and augment corticospinal excitability in people with PD compared to PRBT alone.  
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1.2 Significance 
PD is the second most common neurological disorder affecting 4-6 million people worldwide 
[40, 41]. In Australia, PD affects approximately 90,000 Australians, and has been predicted to 
rise to 240,000 as the aging population grows [41, 42]. As people with PD experience chronic 
impairments in balance and gait, they are at the greatest risk of falls, fractures and long-term 
disability that places a huge financial burden to the individual and the economy. Accordance 
to the Deloitte Access Economics [43], the 2011 health system costs for people with PD were 
$478.5 million; deadweight losses were $121.3 million; productivity costs were $107.3 million; 
other financial costs were $57.1 million; and carer costs were $11.2 million. Therefore, this 
thesis aims to provide preliminary evidence for the combined use of two simple, inexpensive 
and effective strategies to improve gait and balance in people with PD.   
1.3 Research Question 
This thesis addressed two main questions.  These were: 
 Could a 6-week lower limb progressive resistance in combination with balance-specific
training (PRBT) increase step length and step velocity, corticospinal excitability and
cortical inhibition, clinical and functional lower limb performance in people with PD?
 Would the application of a 20 minute a-tDCS over the M1 in concurrent with PRBT
provide additional benefits to step length and step velocity, corticospinal excitability and
cortical inhibition, clinical and functional lower limb performance in people with PD?
It was hypothesised that: 
 A 6-week lower-limb PRBT would increase measures of step length and step velocity,
corticospinal excitability and cortical inhibition, clinical and functional lower limb
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performance in people with PD. 
 
 The addition of a-tDCS with PRBT would facilitate neuroplastic adaptations resulting in an 
increase in step length and step velocity, corticospinal excitability and cortical inhibition, 
clinical and functional lower limb performance in people with PD, beyond that of PRBT 
alone.    
6 
 
CHAPTER 2 LITERATURE REVIEW 
 
2.1 Overview of the Pathogenesis of PD  
In recent years, studies investigating the cause for the sporadic onset of PD has become 
increasingly widespread [44].  Despite the motor symptoms found in people with PD (i.e. 
postural instability, balance, rigidity), understanding how dopaminergic neural cell death 
occurs is still unclear. However, it has been hypothesised that the presence of a-synuclein 
containing Lewy bodies has shown to cause neural death [45-47]. Recently, a study by Luk et 
al. [48] demonstrated how Lewy body formation in mice sufficiently induced substantia nigra 
pars compacta (SNc) dopaminergic neuronal death, as well as form the onset of motor deficits 
that is observed in people with PD [49]  
 
In the SNc, distinct neuronal inclusions called pale bodies that contain sparse granular and 
vesicular filaments have been closely associated with early Lewy body formation in the neuron 
[50, 51]. These filaments are also clearly recognized by anti-a-synuclein antibodies in people 
with PD, whereas in healthy aged adults containing normal neurofilaments show no a-synuclein 
activity [52, 53]. Recently, Mori et al. [54] reported that nearly 10% of neurons in the SNc 
exhibited abnormal a-synuclin aggregates, which also contained both pale body and Lewy body 
formation diffusing in the cytoplasm of a neuron in people with PD [50].  However, from a 
clinical and research perspective, it is still unclear whether the molecular components 
associated to Lewy bodies are implicated in the underlying pathology of PD in humans [45, 
48]. 
 
In addition to Lewy body formation, other factors that contribute to the pathogenesis of PD 
may include ageing [55], environmental [56], and genetic risk factors [57]. Ageing and 
presumed toxic aggregation, such as long-term environmental exposure to pesticides (i.e. 
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chemical and waste management facilities) [55, 58], injury (i.e. physical contact sports) [56], 
is thought to be the predominant cause of PD.  In reference to genetics causes of PD, studies 
have identified that mutations encoded in 6 genes (SNCA, LRRK2, Parkin, PINK 1, DJ-1, 
ATP13A2) are associated with inherited forms of PD [58, 59]. Furthermore, disruption of 
intracellular molecular signaling such as, synthesis of adenosine triphosphate (ATP) (in the 
mitochondria), oxidative stress, fatty acid oxidation, regulation of redox and calcium signaling, 
have also been implicated in dopaminergic neural cell death [60, 61]. 
 
2.2 Symptoms of Parkinson’s disease  
Clinical diagnoses for PD can be based on the presence of 3 to 4 cardinal motor features: 
rigidity (stiffness in the upper and lower limbs), akinesia/bradykinesia (absence /slowness of 
movement), tremor at rest and postural instability, which can be assessed under the Movement 
Disorders Society - Unified Parkinson’s Disease Rating Scale (MDS - UPDRS) [62-64]. As 
the disease progresses, motor complications such as balance and freezing of gait emerges in 
spite of PD medication [62, 64].  Although the current method for treating PD is through the 
use of a drug called Levodopa (L-dopa) [62] to lessen the motor symptoms, long-term use of 
L-dopa has not shown to impact/improve balance and gait in PD [65]. 
 
Additionally, 80 to 90% of patients exhibit other non-motor symptoms such as hyposmia (i.e., 
sensory changes) [66], rapid eye movement behaviour (30 to 50%) [67], mental health issues 
(i.e., depression) [66], and autonomic disturbances, such as constipation, orthostatic 
hypotension, nausea, urogenital problems and excessive sweating [68, 69]. Although, these 
non-motor symptoms can significantly impact upon independent living and reduce ones 
quality-of-life, the motor symptoms exhibited in PD, specifically gait and postural control are 
the primary focus for this thesis. 
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2.2.1 Motor symptoms for PD 
 
The primary motor symptoms of PD can lead to the inability to conduct daily living tasks.  In 
the early stages of PD, resting tremors occur to 70% of all people diagnosed with PD [70, 71]. 
Slight tremors of the hand or foot have been observed on one side of the body, but can also be 
less commonly observed in the jaw or the face [63]. Moreover, tremors can usually consist of 
an oscillating movement or shaking that appears when the muscle is at rest or when body 
movement is relaxed [70, 71]. Resting tremors can be the most visual representation of the 
disease, however not all people with PD develop resting tremors [72, 73], and it is the 
symptoms that impact upon movement speed and quality that have the most detrimental effects. 
One such motor deficit is bradykinesia, or slowness in movement, and is a key defining feature 
of PD [74]. 
 
Bradykinesia can be further sub-categorized into two different states; 1) akinesia (loss of 
movement) and 2) hypokinesia (slow movements) [74].  Bradykinesia can cause difficulty in 
repetitive movements when performing fine motor skills such finger tapping, or hand rotation 
from pronation to supination [75, 76]. Furthermore, the movements observed while walking 
can be of short, shuffling steps limiting someone’s ability to perform complex motor tasks (i.e. 
long strides, walking up steps, walking sideways) [72, 75, 76]. As repetitive movement is an 
apparent feature for everyday living, bradykinesia often has the most significant effect on one’s 
ability to maintain an independent lifestyle and quality-of-life [77]. 
 
Rigidity is another major symptom found in PD [78]. Rigidity in PD is characterised through 
stiffness and inflexibility of the upper and lower limbs. Compared to healthy matched aged 
adults, muscles when performing movement normally stretch, and then relax when at rest [79]. 
However, in people with PD the movement of muscle of the affected limb increases resistance 
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resulting in a constant state of stiffness [80], which contributes to a decrease range-of-motion 
(ROM) [81, 82]. In addition, the ability for fluid muscle movement and optimal  ROM is an 
essential property for maintaining balance [83], and without the mechanism for relaxing muscle 
tone, people with PD not only have a reduced ability to balance, but also to recover quickly 
from a fall [79]. 
One primary motor symptom associated with PD is postural instability [63], which in the course 
of the disease affects at least 96% of all people with PD [84]. The ability to maintain posture 
correlates with the production of muscle reflexes to remain active in order to maintain an 
upright posture [85]. In some instances, the failure of muscle reflex may cause a backward fall 
if physically jostled or when initiating a backwards movement (i.e. opening a door) [85, 86]. 
Furthermore, studies have shown that people have a tendency to sway backwards when 
attaining an upright position from a seated position [87, 88]. In most instances, postural sway 
dynamics are disrupted in people with PD when turning from side-to-side, pivoting, or making 
quick movements [88].  Due to this increase in postural instability, people with PD often report 
a fear of falling that results in lower rate of physical activity [89]. 
Another important factor associated to the incidence of falls and contributes to the motor 
symptoms in PD is freezing of gait [63]. In recent studies, at least 40 to 60% of people with PD 
experience freezing of gait [90-92], which occurs temporarily while in movement [93]. 
Specifically, a person’s gait can be disrupted prior to gait initiation [94], pivoting to opposite 
directions [95], performing another task while walking (i.e. talking on the phone), and when 
approaching elevated walkways [93, 95]. Studies have also found that the freezing action can 
closely resemble akinesia (i.e. absence of movement) representing the inability to suddenly 
start walking or fails to continue to move [63, 74]. In this instance, freezing of gait decreases 
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functional ability for movement, resulting in a high risk of falls [93].  Due to the motor 
symptoms, and injuries that are associated with PD, presents the demand for treatments 
designed to improve one’s health and quality of life.   
 
2.3 Surgical and pharmacological treatments for PD  
Identifying the most effective treatments for improving the motor symptoms (i.e. balance and 
gait) in PD is an ongoing debate in the field of clinical neuro-rehabilitation [45, 68]. While 
most people with PD undergo pharmacological therapy upon diagnosis, others may opt for the 
use of surgical intervention (i.e. deep brain stimulation [DBS]) to treat symptoms that may be 
too severe to treat with medication or drug-resistant [96-98]. This approach uses a battery-
operated device which acts as an electrical stimulator that is surgically implanted in onto 
various locations of the basal ganglia system depending upon the type of symptoms the 
individual suffers from [99-101]. However in Australia, the cost of DBS implantation is high, 
ranging from $7,000 - $30,000 out-of-pocket expense [43] and the procedure is highly invasive.  
Moreover, DBS is only implemented as a last resort when individuals do no respond to L-dopa 
therapy [99, 100].  
 
To date, the use of L-dopa is the current method for treating the motor symptoms and other 
non-motor symptoms associated with PD [102]. Levodopa is an oral medication that is used as 
a precursor to DA [103]. This form of treatment is used to increase DA concentrations in the 
CNS, which is converted by an enzyme called DOPA decarboxylase [103, 104]. It is also 
common for L-dopa to be used in conjunction with another related oral medication called 
carbidopa, which helps L-dopa to bypass the blood-brain barrier and reduce the side-effects of 
L-dopa consumption [105]. Although, the combination of L-dopa and carbidopa are the main 
forms of treating the symptoms in PD and can be used at all stages of the disease, long-term 
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usage has shown to reduce the effectiveness of the drug [103]. Moreover, studies have shown 
that prolong use of L-dopa can be linked to psychosocial impairment (i.e. hallucinations and 
confusion) in patients with PD [106]. Most importantly, recent evidence has further shown that 
the use of L-dopa has no affect for improving balance and gait [107], and has also been known 
to induce levodopa-induced dyskinesia [108]. 
 
2.4 Exercise intervention for the treatment of PD 
Currently, the approach to improve motor impairment in PD has brought its attention towards 
a much more feasible and practical manner. Non-pharmacological interventions such as 
physical activity has been widely accepted as a form of rehabilitation in various neurology 
populations [109]. In particular, exercise or physical activity that incorporates goal-based 
elements (i.e. repetition, intensity, challenge) together with skill training has shown to improve 
motor function and performance in people with PD [110], which can be measured functionally 
and clinically (i.e. timed-up-and-go [TUG] and five times sit-to-stand test [FTSTST]) and 
illustrates the possibility of how exercise can augment neuroplastic changes in the brain  
(Section 2.5, page 28 provides a more detailed review of current literature regarding 
neuroplasticity in people with PD). Furthermore, the use of progressive resistance in 
combination with balance-specific training (PRBT) has been shown to exhibit improvement in 
lower limb strength in people with PD [111-113], which can be observed by conducting a 1-
reptition maximum test (1RM) of the targeted muscle site.  Similarly, task specific training (i.e. 
balance and functional training) has entailed dramatic improvements for balance control [111], 
gait initiation [112], and gait speed [109], which correlates with a reduced hospitalisation cost 
in fall related incidence [89].  
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While there are advantages of utilizing different exercise modalities to improve physical 
function (i.e. gait, balance, mobility), in older and in clinical populations, the overall evidence 
from the literature, particularly those in PD, suggest that the exercise intensity, frequency and 
volume should be tailored to the individuals specific needs [114].  Exercise specialist should 
also take account the outcomes of improvement (i.e. gait, functional mobility, leg strength) 
after various forms of strenuous exercises, and how it may impact ones quality of life once the 
intervention has been completed.    
2.4.1 Progressive resistance training 
Progressive resistance training is a low cost technique used in neuro-rehabilitation in various 
movement disorders [109, 112]. In contrast to non-invasive techniques (i.e. tDCS), PRT is 
highly effective when supervised by a trainer in the exercise field.  This is to induce proper 
execution and technique of body movements when performing specific exercises (i.e. balance 
and lower limb strengthen).  Specifically, the use of high intensity PRT has shown to improve 
lower limb strength [113], balance [115], and improve gait initiation and gait speed [18] in 
healthy aged adults. A recent study conducted by Kirk et al. [116], demonstrated that the use 
of explosive PRT during a 12 week program increased lower limb muscle strength, and force 
production shown in gait kinematics in adults with cerebral palsy. This demonstrates how PRT 
may improve muscle strength production, which in turn increased movement velocity during 
active movement particularly in clinical populations with neurological deficits.  In comparison 
to matched aged adults, people with PD exhibit significant muscle weakness, which can 
manifest in a reduction of muscle power [117], the initiation of movement speed [22], and 
muscle torque [67]. 
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In recent reviews, studies supporting the use of exercise intervention have found an 
improvement in muscle strength [67], gait initiation [13], and gait speed following PRT in 
people with PD [19]. Similarly, Corcos et al. [10] conducted a large randomized controlled trial 
in 38 patients with severe to moderate PD and showed a significant improvement in the Unified 
Parkinson’s Disease Rating Scale (UPDRS)  following a whole-body PRT intervention.  In 
addition, recent studies have indicated a beneficial effect for the use of PRT to improve muscle 
strength, improve muscle mass [26], endurance [10], posture and balance [23] in people with 
PD when targeting lower limb function and performance [19, 26].  
 
More recently, a Meta-Analysis [118] was conducted as part of this thesis (refer to appendix 
A), investigating the effects of lower limb PRT in people with PD. Our findings indicated 
significantly improvements in lower limb strength, however, no additional improvements were 
found in gait and balance following a PRT intervention alone [118]. Only one study by 
Schilling et al. [13] demonstrated a favourable effect for the use of PRT to improve gait speed 
in people with PD. In a more recent study, evidence shows how a 24 month PRT program 
increases muscle activation of the lower limbs in which gait was improved during the 
acceleration phase of movement in people with PD [119]. Although improvements may have 
occurred in lower limb function, gait velocity and magnitude, no significance was 
demonstrated in balance and the time taken to perform each functional measure (TUG and 
FTSTST). It is likely that conducting PRT alone, may not be sufficient enough to induce gains 
in both gait and functional balance and maybe beneficial to incorporate a combination of 
functionally-relevant exercises designed to improve gait and functional balance skills. Indeed, 
studies investigating the use of PRT in combination with other functional exercises such as 
balance training, and stretching in healthy individuals have shown to improve lower limb 
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strength function [18, 25], decreased postural sway and reduced amount of falls [26], and 
improved one’s quality of life [22, 26] that is beyond PRT alone. 
 
2.4.2 Balance-specific training   
Balance is a major component in physical activity and movement that is often implicated in 
falls particular in older adults and people with PD [120]. The ability to maintain the centre of 
gravity with minimal postural sway is essential for mobility and functional performance in 
everyday life [121, 122], for which there are many forms of balance training designed to 
improve postural control, muscle strength, and muscle endurance [117, 122]. Traditionally, 
balance training consisted mainly of a static position held for an extended period of time that 
concentrated on maintaining adequate posture and improving neuromuscular control [115]. 
Recently, there is evidence to support the use of both static and dynamic balance exercises to 
improve postural control [16], improve motor performance [26], and limit the prevalence of 
falls in healthy aged adults [14, 123]. 
 
In particular, balance-specific training (BT) involving multiple body movements that can 
increase lower limb coordination [111], and reduce postural sway in healthy aged adults [120]. 
Similarly, functional skill training involving tasks that are designed as activities performed in 
daily life are components used in rehabilitation for various neurological disorders [20]. Most 
certainly, functional training in combination with balance (if performed correctly) can lead to 
significant improvements in joint mobility [15], postural stability [115] and limb coordination 
[121, 122].  It is important to note that the combination of balance and task-specific training in 
a rehabilitation setting has been employed successfully in other clinical populations such as 
stroke [124] with the aim of improving neuroplasticity [31, 125].  One such study by 
Conradsson et al. [126], investigated how a short-term 10-week program with an emphasis on 
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motor and cognitively challenging balance-specific exercises significantly improved balance 
and gait velocity during normal and dual-task gait in individuals with PD. In addition, BT 
involving static and dynamic movements while performing another task (i.e. dual-tasking) may 
improve neurological function and spatial awareness during simple tasks (i.e. walking and 
talking) in healthy aged adults [127, 128]. 
 
2.5 Neuroplasticity in PD 
The human brain has the natural ability to reorganize itself both functionally and structurally 
through a process known as neuroplasticity [129]. Neuroplasticity describes how daily 
experiences or any forms of external stimuli (i.e. exercise) can reorganize functions of the CNS 
through active learning [129, 130]. The association of neuroplasticity is not limited to a single 
type of morphological change, but rather, includes a wide spectrum of structural and functional 
mechanisms that occur throughout ones lifespan [131]. Such mechanisms are often associated 
with the learning experience or stimuli that strengthens and over repetitive practice, specifically 
the M1 and corticospinal tract [131, 132]. In general, genetic factors, learning environment, 
and age are all key factors that can influence neuroplasticity [133]. 
 
In PD, the function of endogenous dopamine within the basal ganglia system, in particular its 
implications on neuroplasticity, has previously been recognized [108].  Indirect evidence from 
electrophysiological experiments on animal models has demonstrated impairments in 
neuroplasticity and increased parkinsonian symptoms that parallel the loss of endogenous 
dopamine or pharmaceutical blockage of dopamine receptors [134-136]. However, the 
impairments to neuroplasticity and disease symptomology may be ameliorated by the use of 
exogenous dopamine therapy [137]. More recently, direct evidence gathered from PD patients 
undergoing deep brain stimulation further confirmed the role of dopamine on neuroplasticity. 
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A study by Prescott et al. [138] demonstrated that while high frequency stimulation of the 
striatum failed to increase evoked potential amplitude from the sub-thalamic nucleus, high 
frequency stimulation in conjunction with exogenous dopamine was able to induce a lasting 
potentiation in evoked potential amplitude.  
  
It is clear that dopamine within the basal ganglia circuitry plays an important role in 
maintaining and regulating neuro-plasticity. However, the implications for the loss of 
dopamine may also be observed in the cortical regions of the brain. In particular, several studies 
have highlighted the role of dopamine in the M1 and its influence on motor skill acquisition 
and neuroplasticity [139, 140]. A study by Hosp et al. [141] demonstrated that when the ventral 
tegmental area of the midbrain in rats was lesioned, a loss in motor learning ability was 
observed. As dopamine receptors in the M1 receives direct dopaminergic projections from the 
ventral tegmental area, it was suggested that a loss of dopamine in the M1 hindered learning of 
a new motor skill, but not the recollection of a previously learnt movement. This was also 
supported when L-dopa was administered directly into the M1 and motor learning was restored.  
  
In humans, electrophysiological studies on PD patients have also provided evidential support 
for a loss of neuroplasticity in the M1 and reduced motor learning capability. Such studies have 
often utilized non-invasive brain stimulation techniques and have consistently reported of the 
lack of changes to corticospinal excitability [142-144]. Whereas in a normal population, such 
stimulation paradigms would often induce a facilitatory effect on corticospinal excitability and 
motor learning that would normally be indicative of neuroplastic events occurring within the 
M1 [145, 146]. In contrast, evidence from neuroimaging and TMS studies has demonstrated 
an altered pattern of cortical activation in pre-motor areas of the brain [147, 148], increase in 
bilateral activation of the primary sensorimotor cortex during voluntary movements [149-151], 
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and also changes in topographical representation of motor maps in the M1 [152]. These changes 
in cerebral activation and motor representation are thought to reflect a process of cortical 
reorganization that is compensatory in nature and also highlight the propensity for neuroplastic 
change in PD. The evidence suggests that although the presence of dopamine in the M1 is 
paramount to motor learning and plasticity, reorganization of motor representations and 
cortical activation still persists through compensatory neural mechanisms. 
 
2.6 Transcranial direct current stimulation  
The use of tDCS over the M1 is one of the simplest, and most cost effective non-invasive 
technique used for modulating cortical excitability in the brain [37, 153]. TDCS is a painless 
neuromodulation technique consisting of a low intensity direct current being passed by two 
surface electrodes [37, 38]. By altering the position and polarity of the positive electrode 
(anode) [154] and the negative electrode (cathode) [155] over the M1, tDCS is able to increase 
or suppress corticospinal excitability for a period of time after stimulation. In a 
neurorehabilitation context, the role of tDCS acts as a primer to improve motor performance 
and learning by upregulating corticospinal excitability.  
 
While most studies using tDCS in PD are still preliminary, these studies often indicate an 
improvement in motor function following single-session application of tDCS [156-158]. In 
particular, several studies have showed that when anodal tDCS (a-tDCS) was applied during 
or prior to physical training [159], significant improvement in the TUG tests were shown [160]. 
More importantly, these studies further highlighted that the TUG test performance were better 
maintained after a period of time following a-tDCS in comparison to a sham tDCS group [160, 
161]. Further studies have also noticed improvements in the Sit and Reach Test (SRT), 
Standing Stork Test (SST), Four Square Step Test (FSST), and TUG after a 25 minute physical 
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therapy session combined with a-tDCS [162]. In a similar manner, the use of single-session a-
tDCS, was associated with a significant improvement in finger tapping performance in people 
with PD [163]. In a more recent study investigating the effects of a 13 min a-tDCS in 
combination of cued gait training on a treadmill, found a positive correlation between changes 
in cortical excitability and changes in functional mobility in people with PD [164].  
 
Although these studies were acute in nature, it provides a basis of support for the use of a-tDCS 
to improve motor function in people with PD. It is therefore logical to postulate that the addition 
of a-tDCS during functional training will help to facilitate corticospinal excitability and further 
improve motor performance compared to motor training or practice alone. There is certain 
evidence for the combination of tDCS and functional training in healthy aged adults, for which 
Goodwill et al. [39] demonstrated greater visuomotor tracking performances with a-tDCS 
compared to sham stimulation. Another recent study by Schabrum et al. [165], showed how a 
20 min a-tDCS combined with a dual-tasking gait-training under various conditions (i.e. 
counting backward, work list) improved gait performance (gait speed, step length) and TUG 
under all duel task conditons. Although, no difference occurred between the a-tDCS and sham 
group when comparing gait and functional measures, the active a-tDCS group did however 
increase the correct response rate during each duel-task condition.  Recently, a study by Costa-
Ribeiro et al. [159], investigated how a 13 min of 2 mA a-tDCS over the M1 in combination 
with cue gait training shows positive changes in gait velocity, cadence, and TUG in older 
adults.   
 
Further studies that incorporate array of various forms of functional modalities (i.e. visual 
cuing, gait training) in combination with a-tDCS have found similar improvements in gait and 
balance dynamics compared to exercise and a-tDCS alone. One such study by Duarte et al. 
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[166] demonstrated that when applying a 20 min a-tDCS on the M1 combined with a 20 min 
unsupported treadmill training at 80% of maximum speed in children with Cerebral Palsy (CP) 
found improvements in both static and functional balance when evaluated through the 
Paediatric Balance Scale (PBS).  Similarly, Grecco et al. [167] illustrated that a 20 min 
treadmill training at 80% velocity, combined with a-tDCS over the M1 exhibited improvements 
in gait velocity, cadence and global kinematics in children with CP.  Further evaluation found 
that functional mobility was significantly greater in the six-minute walk test post-intervention, 
compared to the children in the control group.  However, considering how the combination of 
a-tDCS and other functional training modalities promotes motor performance and collectively 
cognitive demands during duel-tasking and other functional movements (i.e. visual cuing, gait, 
treadmill training), we are still unaware of what further benefits it may have in people with PD. 
It is currently not known if the addition of a-tDCS during functional training and other physical 
activities will further augment corticospinal excitability in people with PD that will result in a 
significant improvement in gait, balance and postural control. 
 
2.7 Measuring corticospinal excitability using TMS 
The earliest attempts to study the neural integration of the CNS and its involvement in motor 
performance were performed using open surgery on animal models [168, 169]. These studies 
would involve the removal of the skull (in order to make contact with the brain tissue) so that 
electrodes could be placed directly over the site(s) to be stimulated. Due to the invasive nature 
of the procedure, other studies have tried to induce electrical stimulation without open surgery, 
but to limited success.  
 
Merton and Morton [170] became the first to succeed in using transcranial electrical stimulation 
(TES) to stimulate the M1 without removing the scalp. The procedure involved placing two 
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electrodes over the scalp and using a high voltage current to bypass the scalp and skull into the 
cerebral cortex. Although successful, the procedure proved to be very uncomfortable as most 
of the current would flow between the two electrodes causing localised pain and contraction of 
the scalp muscles. It was not until five years later that Barker and colleagues [171] used 
Faraday’s principle of magnetic induction to safely and painlessly deliver electrical 
stimulations across the scalp and skull. 
 
According to Faraday’s principle of electromagnetic induction, a changing magnetic field is 
required to induce an electrical current in a nearby circuit [172]. For transcranial magnetic 
stimulation (TMS) to occur, a high-current pulse is produced in a magnetic coil (coil of wires) 
that is placed tangentially across the scalp. The magnetic fields produced by the coil generate 
fluxes that run perpendicular to the field. The rapidly changing magnetic fields induce a 
secondary loop of electrical current, which travels parallel to the plane of the coil. This brief 
electric current evoke pulses in the brain, which can trigger action potentials in cortical 
neurons, particularly those found within superficial areas of the cerebral cortex that briefly 
excite or inhibit neural activity [173, 174]. This brief electrical pulse in the M1 produces 
descending volleys in the corticospinal tract that triggers a contraction to a specific muscle 
region [174, 175]. (Figure 2.1A illustrates how descending volleys can occur using TMS). The 
muscle contraction then elicits a motor-evoked potential (MEP), which can be recorded by a 
surface electromyography (sEMG) that is positioned at a specific muscle site [176, 177]. 
(Figure 2.1B illustrates an MEP recorded from a surface EMG).  
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Figure 1. (A) TMS using a double cone coil placed over the M1 to produce descending volleys in the spinal cord to a targeted muscle region to 
produce an MEP response that can be recorded through surface electromyographic (sEMG) recording. (B) Representation of a MEP during 
voluntary contraction of the muscle. The TMS stimulus (i) is followed by a brief period of MEP latency (ii), before the peak-to-peak amplitude of 
the MEP shown at (iii). The silent period (iv) is measured from the onset of the MEP, to the return of background sEMG (v) (Illustration modified 
from Klomjai et al. [178] and Wilson et al. [179]). 
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In response to the intensity of TMS, the reflection of MEP amplitude gives researchers the 
opportunity to distinguish changes in excitability of the corticospinal pathway [153, 180].  
These recorded changes can be assessed by examining the following properties (see Figure 1): 
1. Latency, this represents the corticospinal conduction time from the M1 to the targeted 
muscle site. 
2. Motor threshold (MT), which can be used to quantify corticospinal excitability during 
a resting or active muscle state. 
3. MEP amplitude, a relation to the strength of corticospinal projection onto the motor 
neuron pool. 
4. MEP silent period, which represents corticospinal inhibition at the M1 and along the 
spine.  
 
2.7.1 Single-pulse TMS 
Direct recording of the output from the M1 demonstrated that Transcranial magnetic or 
electrical stimulation could evoke different responses of descending activities depending on 
the modality (electrical vs. magnetic) and intensity of stimulation [181, 182]. Earlier 
investigations on experimental animal models have showed that in response to a single 
electrical stimulation, distinct volley of waves may be observed [168, 169]. The study of these 
descending waves, termed “D” wave and subsequent “I” waves due to where they originate 
from, have provided detailed insights to the physiological mechanisms involved with the 
interactions of various cortical motor networks.   
 
In humans, the study of transcranial stimulation responses have been performed on patients 
that were undergoing spinal cord surgery [181, 183], and more recently, on patients who have 
had electrodes implanted in their spinal cord for the relief of chronic pain [182, 184]. The 
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generation of D-waves were found primary via direct stimulation of the pyramidal tract 
neurons, although in more recent experiments, D-waves were also recorded from TES [185] or 
with TMS that induces a lateromedial current flow in the brain and at high stimulation 
intensities [182].  In contrast, the generation of subsequent I-waves is thought to originate from 
indirect, transynaptic excitation of pyramidal track neurons [186-188]. 
 
In addition to measuring responses evoked by TMS, stimulation of the peripheral nerve also 
provides additional information regarding the status of excitability along the neuromuscular 
pathways. It must be noted that since the neuromuscular system is comprised of both the CNS 
and working muscles, any changes in MEP recording to TMS may be reflective of excitability 
changes either at the central, spinal, muscular level or a combination of all of the above. 
Therefore, to exactly pinpoint the level at which change occurs, recordings from at the 
cervicomedullary junction and peripheral nerve stimulation are sometimes performed in 
conjunction with TMS [189].  
 
In a recent update by Rossini et al. [190], evidence suggests that after reliable diagnostic testing 
MEP amplitude measured at single TMS intensity showed no increase of corticospinal 
excitability, but rather expressed as a percentage of an individual’s MT when facilitated at rest 
and active.  Further studies have also shown that the application of single-pulse TMS had a 
normal central motor conduction time, but displayed shortened levels of the cortical silent 
period in people with PD [190, 191].  Similarly, a study by Ni et al. [192], observed how when 
applying single pulse TMS to the M1, the recorded measures showed normal MEP threshold 
response during OFF and ON medication for people with PD.  However, MEP amplitude 
during single-pulse TMS indicated an increase during ON and OFF medication, and a decrease 
in silent period during OFF medication, but exhibited an increase during ON medication [193]. 
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2.7.2 Paired-pulse TMS 
Similar to single-pulsed TMS, paired-pulse TMS is performed by delivering two magnetic 
pulses at a set inter-pulse interval (IPI), which normally ranges from 1 millisecond (ms) to 300 
ms [194]. Paired-pulse TMS paradigms (usually involving a preceding conditioning stimulus 
[CS] followed by a test stimulus [TS]) are normally used to provide detailed information about 
the inhibitory neural circuitry of the corticospinal pathways. This is especially useful when 
investigating the phenomenon of cortical inhibition, otherwise known as short-interval cortical 
inhibition (SICI).  
 
SICI is a brief moment of inhibition after paired-pulse TMS is applied at a specific IPI [195]. 
For SICI to occur, two pulses (CS-TS) with an IPI of 3 ms or less must be applied. The CS is 
a sub-threshold stimulus that is thought to activate inhibitory interneurons that synaptically 
modulate activity of corticospinal neurons [194]. The CS intensity is only strong enough to 
stimulate the cortical region and suppress the generation of I-waves [196], but not strong 
enough for it to descend down the spinal column [197]. The test stimulation is usually a supra-
threshold stimulation whereby a recording can be seen at the muscular level. The first priming 
sub-threshold stimulation excites inhibitory neurons (GABAergic neurons) causing the release 
of gamma - Aminobutyric acid (GABA) at its synaptic junction. The uptake of GABAA, which 
is part of a ligand-gated ion channel complex on the dendrite is mainly responsible for a short-
term inhibition or a down-regulation of MEP in the second pulse [198, 199]. 
 
The threshold for inducing SICI (lowest CS intensity to cause MEP suppression of TS) is on 
average about 70% of active motor threshold [200] and with maximum suppression occurring 
at approximately 80% resting motor threshold (RMT) [195]. The initial increase in CS intensity 
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causes a greater facilitation of SICI until the CS intensity reaches about 90% of RMT before 
SICI starts to decline again [195]. The decline of SICI at higher CS intensity is thought to be 
due to the activation of descending volleys that produces subthreshold activation of spinal 
motoneurons, although it is found that there can be widespread inter-subject variability in the 
index of SICI [200].  
 
Furthermore, the modulation of SICI is also greatly influenced by voluntary movements. 
During voluntary contractions, the effects of SICI are attenuated as well as prior to the onset 
of the movement [201-203]. The opposite effect is observed after cessation of the movement 
task [204]. These findings suggest that the reduction in SICI before and during movement may 
serve as an adaptation to increase central motor drive. As well, increased SICI has also been 
reported in muscles that are not involved in performing the task [205, 206]. The implication 
for this effect suggests that intra-cortical inhibitory circuits may help to reduce unwanted 
activation when performing task-specific activities. Further reports have shown that the 
application of paired pulse TMS over the M1 have found that post-synaptic inhibition 
decreased during ON and OFF medication [192, 193]. This suggest that after a high CS 
intensity has been administered a greater SICI occurrence can be shown, which can be 
interpreted to a reduction in post-synaptic inhibition [192, 207].   
 
2.8 Summary of Literature  
As the aging population continues to grow, the effects of the motor symptoms in any 
neurodegenerative disease generates a high risk to the overall health and wellbeing of those 
trying to live independently.   Currently, studies using animal models and neuroimaging 
techniques are searching ways to find biomarkers for neurodegenerative diseases, particularly 
those diagnosed with PD [208].  There has been much research involved in the previous years 
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for investigating the delivery of therapeutic interventions (i.e. resistance training, non-
invasive stimulation) for the treatment of motor symptoms that are found in PD today.  
Progressive resistance training (PRT), with the combination of other exercise modalities (i.e. 
balance-specific training) provides a reasonable and simple process to actively engage in 
physical and progressive activities.  Physical training interventions gives us a foundation to 
acquire other novel techniques (i.e. tDCS, single and paired pulse TMS) that have been 
shown to have considerable effects on the motor symptoms found in PD.  Particularly the use 
of PRT [209] and the combination of balance-specific (BT) [126] training with non-invasive 
techniques [210] are known therapies for the improvement of strength, motor function and 
modulating neural activity in PD. Furthermore, the variability of  single and paired pulse 
TMS to measure cortical and inhibitory responses in PD after the use of various interventions 
(i.e. PRT, BT, a-tDCS) have demonstrated desirable outcome [175], and illustrates the need 
to pursue interventions designed to improve motor functioning in people with PD.  
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CHAPTER 3 METHODS 
3.1 Study design 
This thesis was part of a larger randomised controlled trial, the delivery of this thesis 
methodology and experimental design was adapted from a recent publication by Hendy et al, 
[211] (appendix B). 
 
3.2 Participants 
A total of 33 participants aged between 50-80 years were selected on a voluntary basis, through 
the Australian Parkinson’s disease registry (APDR) (Refer to appendix C for participant full 
demographics). The APDR is a national database of people with PD that consists of more than 
400 members within Victoria. The APDR has assisted in this project in the recruitment of all 
the participants that were involved in the study, by being the first point of contact that met our 
inclusion criteria. Participants were also recruited through local neurology clinics within the 
Melbourne metropolitan area.  
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Prior to partaking in the study all participants were screened with the following 
questionnaires (Refer to appendix D – F for details of questionnaires) and inclusion/exclusion 
criteria: 
1) An Adult TMS Safety-Screening Questionnaire 
2) The Deakin University Medical Questionnaire 
3) The Mini-Mental State Examination (MMSE) 
 
The inclusion criteria for PD participants included: 
1) A proven diagnosis by an independent neurologist;  
2) Hoehn & Yahr score ≥ 2-4;  
3) Stable drug regimen prescribed by their neurologist;  
4) Prior history of one or more falls in the last 2 years; and  
5) Not receiving any other physical therapy or regular exercise.   
 
The exclusion criteria included:  
1) Early stage of PD (Hoehn & Yahr score < 2);  
2) Severe lower limb motor impairments (i.e. requires a walking support or wheelchair 
bound);  
3) Previously diagnosed with stroke or dementia;  
4) Metal implants in the participants head (i.e. deep brain stimulator or aneurysm clips);  
5) Other medical conditions or physical disabilities interfering with the participant’s 
mobility. 
 
Once participants were deemed eligible for the study, they were provided with a Plain 
Language Statement (appendix G) for which they were given up to 7 days to decide if they 
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wished to partake in this trial. If a participant wished to enrol into the trial, written informed 
consent was provided. In addition, all PD participants provided approval to partake in physical 
exercise from their doctor prior to participating in this study. Ethical approval for this study 
was granted by the Deakin University Human Research Ethics Committee (Project ID- 2014-
014).   
 
3.3 Randomisation and organisation of the study 
Once a participant was deemed eligible to participant in the trial, a computerised sequence 
generator on Microsoft Excel 2016 was used to randomise participants into 1 of 3 groups;  
1) Progressive resistance/Balance-specific + tDCS group (Ex+tDCS) 
 
2) Progressive resistance/Balance specific + sham tDCS group (Ex+Sham) 
 
3) Usual care group (Control) 
 
After allocated, opaque envelops was used to conceal the group allocation, which was not 
revealed until after all data was analysed. A researcher who was otherwise removed from the 
study intervention programed the a-tDCS machine before PRBT sessions to ensure double-
blinding of the researcher who was involved with conducted the training; any assessors who 
assisted in the training; and the participants. The study was designed to run for 9 weeks in total. 
This included 1 familiarisation session (30 mins) to introduce all participants to the exercises, 
18 training sessions (3 times a week for 6 weeks, approximately 30 mins per session), and 4 
testing sessions (0 week [baseline], mid- intervention [3 weeks], post-intervention [6 weeks] 
and follow-up [9 weeks]).(Figure 2 gives study timeline of measurements). 
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Figure 2: Study timeline and overview of exercise intervention and measurements 
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3.4 Training sessions 
All progressive strength training exercises were aimed at the lower body, which included leg 
press, squats, standing calf raises, and seated foot raises, which were performed on either fixed 
gym equipment, free weighted dumbbells or weight vests. Participants performed 3 sets of 6-8 
repetitions of each exercise (3 secs concentric, 3 secs eccentric paced externally using a 
metronome) with the machine and free weights performed at 70% of their recorded 1-RM. 
Between each set of PRT exercises, participants also performed progressive balance tasks on 
either an airflex pad, duradisc or Bosu ball. The sections below describes the types of activities 
within each PRT and balance-specific training. Further, all training and testing sessions were 
conducted approximately 1 hour after consuming PD medication during the “ON” phase. 
 
3.4.1 Progressive resistance training 
Exercise progression for PRT were performed as follows (refer to appendix H for all PRT 
exercises). All exercise were only advanced to the next progression when participants were 
able to perform each progression stage confidently. Progression of exercise was based off of 
the guidelines released by American college of sports medicine (ACSM) [212]. 
1. Leg press-  
a. 3 sets of 6 repetitions at 70% of 1RM;  
b. Increase weight by 5% when all 3 sets can be completed with correct technique.  
2. Calf raises-  
a. Start with 3 sets of 6 body weight calf raises, both legs with full range of motion;  
b. Add 5kg and then 10kg weight vest;  
c. Perform single leg without assistance;  
d. Single leg, add 5kg and then 10kg weight vest.   
3. Ankle dorsiflexion-  
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a. 3 sets of 6 reps at 70% 1RM (unilateral);  
b. Increase weight by 5% when all 3 sets can be completed with correct technique.   
4. Squats-  
a. 3 sets of 6 ‘sit-to-stands’ onto a bench with just bodyweight;  
b. 3 sets of 6 squats (use bench to guide, but not sitting down);  
c. Add 5kg weight vest, and balance component (airflex pad);  
d. Add 10kg weight vest, with balance component (duradisc or Bosu ball) with 
trainer assisting for balance;  
e. Add 10kg weight vest, duradisc or Bosu ball with no trainer assistance;  
f. Single leg on duradisc or Bosu ball with trainer assistance.  
 
3.4.2 Balance-specific training 
Balance training progression was performed as follows. Similar to the exercise progressions, 
participants only advanced to the next progression when they could confidently complete the 
current stage (Refer to appendix I for all balance exercises). 
1. Tandem stance- 
a. 4 x 15 secs tandem stance, alternating leading foot;  
b. addition of airflex during tandem stance;  
c. Perform task with eyes closed using airflex or duradisc;  
d. Add multidirectional perturbation while standing on airflex or duradisc.   
2. Single leg stance- 
a. 4 x 15 secs single leg stance (with assistance); 2)  
b. Add randomised multidirectional toe-taps at 12 o’clock, 1 o’clock, 2 o’clock 
and 3 o’clock;  
c. Add ball rolls (in circular motion using only one foot);  
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d. Single leg using airflex, or duradisc;  
e. 5) perform task using airflex, or duradisc with eyes closed.   
3. Tandem walk-  
a. 3 x 12 steps, heel-to-toe walk in a straight line;  
b. Heel-to-toe walk concurrent with perturbation and dual-tasking (i.e., naming 
words starting with the letter B, car brands, counting backwards by 7’s).   
4. Hurdle walk-  
a. 6 laps of 4 hurdles (add ankle weights);  
b. Increase hurdle height (15cm and 30cm)  
c. Add dual-task (naming suburbs of Melbourne, countries); 4) side-ways walk.   
 
3.4.3 Standard care group  
PD participants that were assigned to the standard care group only participated in testing 
sessions. Participants that were assigned in the standard care group was asked to continue their 
dietary, medical and day-to-day activities as per usual.  
 
3.4.4 tDCS application  
Prior to the start of each training session, the anode was placed on the M1 that was connected 
to a hand-held, battery operated DC stimulator (TCT-Research Constant Current Generator – 
RES 4.50mA, Figure 3). The anode was positioned over the vertex that corresponds to the 
optimal site of the leg motor representation, and the cathode was positioned on the right 
shoulder. The tDCS intensity was incrementally ramped up to 2 milliamps (mA) and 
maintained for a duration of 20mins in concurrent with the training activities. To perform sham 
tDCS, the intensity of stimulation was ramped up incrementally to 2mA and maintained only 
for 15secs before turning off. This method of sham tDCS provided the initial scalp sensation 
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and was previously validated [213-215]. For all tDCS conditions, participants and researcher 
were blinded to the type of stimulation that the participants had received. 
 
 
Figure 3. Illustration of the tDCS and electrode placement. Anode (red) placed over the vertex 
of the head, and cathode (black) placed on participants shoulder. 
 
3.5 Primary and secondary outcome measures 
All outcome measures in this study were collected at 4 time points (Baseline, 3 weeks, 6 weeks 
and 9 weeks.  All participants were required to take their prescribed medication 30 – 60 minutes 
prior to their scheduled test session.  The primary outcome measures for this study were 
measures of gait specifically stride length and velocity and dual-task cost of both of these 
measures. The secondary outcome measures were clinical and functional assessments that 
included:  
1) Movement Disorders Society Unified PD rating motor subscale III & IV (MDS-
UPDRS-III & IV); 
2)  Timed Up-and-Go test (TUG);  
3) Five Sit-to-Stand test (FTSTST);  
4) Berg Balance Scale (BBS); 
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5) 1 repetition-maximum test (1RM) of the lower limb muscles (see section 3.2.7 Strength 
Assessments);   
6) Peripheral muscle excitability, corticospinal excitability and cortical inhibition.   
  
3.5.1 Gait assessment 
Measures of step length and velocity were collected using an instrumented Zeno walkway 
(ProtoKinetics Zeno system, ZenoMetrics LLC, Peekskill, NY, Figure 4) under 2 conditions – 
1) single task walking, and 2) dual-task walking.  Calculation used to process measures of step 
length and velocity was the mean ± SD for variation.  Step length was calculated as distance 
from ipsilateral heel-strike to contralateral heel-strike in the plane of progression. Step velocity 
was calculated as step length divided by the corresponding duration.  Prior to the gait 
assessment, 2 practice trials were conducted by asking the participant to 1) walk normally up 
and back the walkway once, and 2) walk up and back the walkway while counting backwards 
by 7’s starting from 97. After which, the participant was asked to conduct 2 tasks in a 
randomized order; 1) walking up and back the walkway 4 times for 3 trials and 2) counting 
backwards by 7’s while walking up and back the walkway 4 times for 3 trials. A 30-sec rest 
was given between each trial. To determine dual-task cost (DTC) for stride length and velocity, 
the following formula was used; 
 
DTC = 
(Dual-task step length/velocity – Single-task step length/velocity) 
Single-task step length/velocity  
 X 100% 
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Figure 4.  Example of the setup of the (A) Zeno walkway, (B) participant walking on the walkway and (C) foot-falls recorded during gait.  
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3.5.2 Movement Disorder Society – Unified Parkinson’s disease rating scale 
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS, Appendix J), is the gold standard clinical assessment for PD used 
worldwide, which entails 4 parts (motor and non-motor). However only the motor examination 
(Part III and Part IV) of the UPDRS (MDS-UPRDRS-III and IV) was performed. The MDS-
UPDRS-III consists of the following questions that was performed by the participant in front 
of the examiner: 
1. Speech: The examiner engaged in conversation with the participant to evaluate his/her 
volume during talking, modulation and clarity, slurring, repetition of syllables, and 
tachyphemia (rapid speech, running syllables together). 
2. Facial expression: The participant was asked to sit in a casual position while the 
examiner observed if the participant exhibited spontaneous smiling, parting of lips, loss 
of facial expression, and masked faces for 10 secs while talking and without talking. 
3. Rigidity: This test was judged on the participant’s slowness or passive movements of 
the major joints/limbs (i.e. neck, arms, legs).  The participant was asked to sit in a 
relaxed position while the examiner manipulates the limbs and neck without an 
activation maneuver.  When no rigidity was detected, the use of an activation maneuver 
such as tapping fingers, fist opening/closing, or heel tapping was initiated to a limb not 
being tested. 
4. Finger tapping: The participant was instructed to tap his/her index finger on the thumb 
10 times as quickly and as big as possible.  Each hand was tested separately, and was 
evaluated for speed, amplitude, hesitations, halts and decreasing amplitude. 
5. Hand movements: The participant was instructed to make a tight fist with his/her arm 
bent at the elbow with palm facing the examiner.  Participant was asked to open his/her 
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hand 10 times as fully and as quickly as possible. Each hand was tested separately, and 
rated for speed, amplitude, hesitations, halts and decreasing amplitude. 
6. Pronation-supination movements of hands: Examiner instructed the participant to 
extend arm out in front of his/her body with palms facing down.  Participant was asked 
to turn the palm up and down alternately 10 times as fast and as fully as possible.  Each 
side was rated separately, and evaluated for speed, amplitude, hesitations, halts and 
decreasing amplitude. 
7. Toe tapping: Prior to testing, the participant was asked to sit in a straight-backed chair 
with arms, and placing both feet on the floor.  Participant was then instructed to place 
his/her heel on the ground in a comfortable position and then tap their toes 10 times as 
beg and as fast as possible.  Each side was tested separately, and rated for speed, 
amplitude, hesitations, halts and decreasing amplitude. 
8. Leg agility: Having the participant sitting in a straight –backed chair with arms, the 
participant was asked to place both feet comfortably on the floor. Participant was then 
instructed to raise and stomp his/her foot on the round 10 times as high and as fast as 
possible.  Each side was tested separately, and rated for speed, amplitude, hesitations, 
halts and decreasing amplitude. 
9. Arising from chair:  Participant was asked to sit in a straight-backed chair with arms, 
with both feet placed on the floor and sitting back in the chair with his/her arms folded 
across their chest.  Participant was then asked to stand up from the chair, while still 
keeping his/her arms folded across chest.  The participant was given only one attempt 
to complete the task. 
10. Gait: The Participant was asked to walk 10 meters away from and towards the examiner 
so that both right and left sides of the body was easily observed.  One attempt was 
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given, and participant was assessed for stride amplitude, stride speed, height of foot lift, 
heel strike during walking, turning, and arm swing. 
11. Freezing of gait:  This task is an extension of the ‘gait’ assessment.  While participant 
was performing the gait assessment, the examiner observed any signs for gait hesitation 
and stuttering movements, especially when turning and reaching the end of the task. 
12. Postural stability: Test evaluates the response to sudden body displacement produced 
by a quick, forceful pull on the participant’s shoulders while s/he was standing erect 
with eyes open.   
13. Posture: Evaluation of posture was assessed when the participant was asked to stand up 
from the chair while arms folded across chest.  Participant was rated for flexion and 
side-to-side leaning. 
14. Global spontaneity of movements: This global rating combines all observations on 
slowness, hesitancy, and small amplitude and poverty of movement; including a 
reduction of gesturing and of crossing of the legs. 
15. Postural tremor of the hands: The participant was instructed to stretch his/her arms out 
in front of their body with palms facing down and placing fingers comfortably separated 
from each other for 10 seconds. Each limbs was tested separately, and was rated on all 
forms of tremor, including re-emergent rest tremor. 
16. Kinetic tremor of the hands: This test utilizes the finger-to-nose maneuver.  The arm 
started from the outstretched position, the participant was instructed to perform at least 
3 finger-to-nose maneuvers with each hand reaching as far as possible to touch the 
examiner’s finger. Each limb was rated separately with the movement performed slow 
enough not to hide any tremor. 
17. Rest tremor amplitude: The participant was asked to sit quietly in the chair with hands 
placed on the arms of the chair (not on lap) and the feet comfortably supported on the 
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floor for 10 seconds with no other directives. Evaluation for this assessment was 
purposefully placed at the end of the examination to allow rating for rest tremor that 
may have appeared at any time during the exam, including when sitting, during walking 
and during activities when some body parts are moving but others are at rest. 
18. Constancy of rest tremor: This evaluation is associated to rest tremor amplitude, but 
focuses more on the constancy of rest tremor during the examination when different 
body parts are variously at rest. 
 
The MDS-UPDRS Part IV assesses motor complications, which was divided into 3 parts (Part 
A: dyskinesias; Part B: Motor fluctuations; Part C: dystonia) and the examination was delivered 
immediately after the MDS-UPDRS Part III.  If the participant was deemed not have 
dyskinesias, Part A was disregarded and evaluation resumed at the motor fluctuation section 
(Part B). The evaluation reported during this examinations was as follows: 
 
MDS-UPDRS Part IV Motor complications (Part A): 
This examination was conducted only when the participant showed signs of dyskinesias, which 
can be recognized as “irregular jerking”, “wiggling”, “twitching”, or if the participant has noted 
that he/she has dyskinesias.  It is essential to stress to the patient the difference between 
dyskinesias and tremor. 
1. Time spent with Dyskinesias (exclusive of OFF-state dystonia):   If dyskinesias was 
present, the participant was asked how many hours he/she usually sleeps on a daily 
basis, including night-time sleep and daytime napping.  The participant was asked to 
give a time (hours) he/she spent awake during the past week and during the awake state, 
how many times (hours) did they have wiggling, twitching, or jerking movements.  The 
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time spent with dyskinesias was calculated from the total hours awake and the total 
hours with dyskinesias:  
% Dyskinesias = ([Total Hours with Dyskinesias/Total Hours Awake] * 100). 
2. Functional impact of dyskinesias: The participant was asked whether in the past week 
prior to the examination did he/she usually have trouble doing physical tasks or found 
it difficult being around people during periods where dyskinesias (jerky movements) 
was present. The participant was then asked whether it prevented them from doing 
activities in public or from being around other people. The evaluation was recorded and 
rated from 0 – 4; whereas 0 = Normal, and 4 = Severe. 
 
MDS-UPDRS Part IV Motor complications (Part B): 
This section examined the motor fluctuations during OFF state (variable response to 
medication). Some people with PD may respond well from their medications throughout their 
awake hours (ON state) however other people with PD may take medications but still have 
some hours of low time, bad time, slow time, or shaking time, which is called OFF time.  
1. Time spent in the OFF state:  The participant was asked to give the time (hours) that 
they are generally awake each day during the past week.  Participant was then asked to 
give a time (hours) from the previously stated awake time when he/she usually felt low 
levels or OFF function.  The time spent was calculated from the total hour’s awake and 
total hours OFF:  
% OFF = ((Total Hours OFF/Total Hours Awake)*100) 
3. Functional impact of fluctuations: The participant was asked to think when he/she felt 
low or when OFF periods occurred in the past week.  Participant was asked whether 
he/she had problems conducting certain activities when feeling low, and being around 
42 
 
people, compared to when the medication worked.  The evaluation was recorded and 
rated from 0 – 4; whereas 0 = Normal, and 4 = Severe. 
2. Complexity of motor fluctuations: This evaluation determines the usual predictability 
of OFF function, whether due to dose, time of day, food intake or other factors.  The 
participant was asked when they usually know when low periods will occur.  Values 
were rated from 0 – 4; whereas 0 = Normal, and 4 = Severe. 
 
MDS-UPDRS Part IV Dystonia (Part C): 
This portion of the test examined OFF state dystonia. Examiners observe whether participant’s 
exhibit contorted posture, usually with a twisting component. For patients who have motor 
fluctuations, this evaluation determines what proportion of the recorded OFF episodes usually 
include painful dystonia. 
1. Painful OFF state dystonia: Participant was asked to recall the time (hours) spent during 
the OFF state that he/she felt painful cramps or spasms.  Time spent with dystonia was 
calculated by the total hours OFF and the total OFF hours with dystonia:  
% OFF Dystonia = ((Total OFF Hours with Dystonia/Total Hours OFF)*100). 
 
3.5.3 Timed-up-and go assessment 
For the TUG test, all participants were required to sit on a standardised armchair, placing their 
backs against the chair and resting their arms on the arm-rest.  Participants was required to 
wear regular enclosed footwear as well as customary walking aids if required. Participants were 
then instructed to arise from the chair and walk to a green cone that was placed 3m away at a 
comfortable and safe walking speed, turn around at the cone, walk back to the chair, and sit 
down.  The test ended when the participant assumed the original seating position.  All 
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participants performed 3 consecutive trials of the TUG with each trial being timed and the 
quickest time recorded. 
3.5.4 Berg balance assessment 
The BBS consisted of 14 static and dynamic balance tasks that were scored from 0 to 4. During 
the test, the participant was graded on the following item descriptions: 
(1) Sitting to standing (8) Reaching forward with outreached arms
(2) Standing unsupported (9) Retrieving object from floor
(3) Sitting unsupported (10) Turning to look behind
(4) Standing to sitting (11) Turning 360 degrees
(5) Transfers between chairs (12) Placing alternate foot on stool
(6) Standing with eyes closed (13) Standing with one foot in front
(7) Standing with feet together (14) Standing on one foot
The participant was given instructions that they must maintain their balance while attempting 
each task.  For most of the tasks, the participant was asked to maintain a given position for a 
specific time. During the exam, points were deducted when: 
 The time or distance requirements were not met
 The participants performance warranted supervision
 The participant required external support or received assistance from the examiner
The same assessor performed the test at all-time points and was blinded to the intervention 
group. High validity and reliability of the Berg Balance Scale in neurological patient 
populations have previously been established [216] (Refer to appendix K for the Berg score 
and test sheet). 
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3.5.6 Five Times sit-to-stand test 
The Five Times Sit-to-Stand Test (FTSTST) was used to assess mobility and lower limb 
acceleration. Participants were asked to start at a seated position in a 46-cm chair with armrests 
and was then asked to begin the test with their arms folded across the chest and their back 
upright against the backrest. Participants performed five repetitions of moving from the seated 
position to standing, with the hip and knee joints fully extended as quickly as possible. The 
total time taken to complete five repetitions was recorded in seconds and a total of 3 trials were 
performed with the fastest trial recorded. Previous studies have reported high validity and 
reliability of the FTSTST in patients with PD [217]. 
 
3.5.7 Strength assessment 
All participants performed a 1-repetition maximum (1RM) test to assess maximal strength of 
the quadriceps (Quad), hamstrings (Ham), gastrocnemius (Gas) and tibialis anterior (TA) 
muscles. Each participant performed 1-RM testing in sequence starting with 1) leg press; 2) 
plantarflexion on the leg press machine; 3) leg extension; and 4) dorsiflexion (toe lifts) using 
free weighted dumbbell (refer to appendix L for all strength exercises).  Participants were asked 
to start by practicing the exercise with a moderate weight, with more weight being gradually 
increased by 5-10% each repetition until the participant could no longer perform the exercise 
with correct form.  All exercises were chosen carefully to minimize any risk of falling or injury 
whilst being performed, and was based upon the ACSM guidelines [212]. 
 
3.5.8 Peripheral muscle excitability, corticospinal excitability and cortical inihibition 
The surface electromyography (sEMG)were recorded from the TA muscle in accordance with 
the sEMG for non-invasive assessment of muscles (SENIAM)  recommendations [218] (see 
Figure 5). The area of electrode placement was shaved to remove hair, rubbed with abrasive 
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gel to remove dead skin, and cleaned with 70 % isopropyl alcohol. Bipolar gel electrodes (8-
mm diameter, model E258S; BIOPAC Systems, Goleta, CA, USA) were placed over the TA 
muscle belly with an inter-electrode distance of 2cm. A grounding electrode was placed over 
the patella and used as a common reference. Location of the muscle belly was determined by 
palpating the muscle area while the participant contracted his/her muscle by a lifting and 
lowering motion of their foot.  The electrode was marked with a permanent marker, measured 
in reference to the tibial tuberosity, and photographed to ensure consistent electrode placement 
between sessions. All cables were fastened with tape to prevent movement artifact. All EMG 
signals were amplified (x1000) with bandpass filtering between 5 Hz and 500 Hz, sampled at 
4000 Hz and acquired using LabChart8 (LabChart software, ADinstrument, Australia) via a 
laboratory analogue-digital interface (The PowerLab 8/30 ADinstrument, Australia) for offline 
analysis.  
 
Peripheral muscle excitability was measured using maximal compound waves (M-waves) 
collected during each testing session. A DS7A constant current electrical stimulator (Digitimer, 
Welwyn Garden City, UK) was used to deliver supramaximal stimulation to the common 
peroneal nerve. The head of the fibula was palpated, and a stimulating bar was positioned 
directly inferior, with light pressure applied. Stimulation was delivered at increasing current 
strengths until the muscle response reached a plateau, then increased 10-20 % to ensure 
maximal stimulation was achieved (Mmax), which represents activation of the entire 
motoneuron pool of the muscle of interest.  The largest resulting peak-to-peak muscle response 
was reported as the Mmax and was obtained in resting muscle conditions.  
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Figure 5. (A) Location of the TA based on SEINAM guidelines; (B) Location of bipolar 
electrodes over the TA; (C) Location of the reference electrode; (D) Electrical stimulator 
location to target the deep peroneal nerve.  
 
Single- and paired-pulse TMS of the M1 were conducted using two Magstim 2002 stimulators 
(Magstim Co, UK; Figure 6) to record MEPs in a resting state of the TA muscle of right 
dominant leg. All participants sat upright on a standardized chair with their back against the 
backrest of the chair and their hips, knees and ankle joints in a relaxed 90○ angle. All 
participants then wore a custom-made nylon cap that is marked with a 1 cm concentric grid 
that extends outward from the vertex, for which the vertex was aligned with the midpoints of 
inter-aural and nasion-inion lines. A double-cone shaped coil was positioned directly overhead 
near the vertex of the head as this position corresponds to the motor representation of the lower 
limb. The optimal site-of-stimulation was determined by initial exploration to find the location 
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that produces the largest and most consistent MEP recordings in at least 5 out of 10 stimuli 
[185]. Once the optimal location was found, it was marked and all subsequent TMS testing was 
based off the marked location. The resting motor threshold (RMT) was then identified by using 
the intensity at which 5 out of 10 stimuli produces a MEP amplitude between 50 to 100 μV 
[185]. Once the RMT was ascertained, 10 TMS stimulus was delivered at 130% of RMT to 
provide a measure of corticospinal excitability. The average of all 10 single-pulse MEP 
amplitude was normalised and presented as a percentage of Mmax to eliminate any change in 
muscle excitability acting as a confounder when determining corticospinal excitability [219].  
 
 
Figure 6: (A) measurement of apex using custom-made nylon cap that is marked with a 1 cm 
concentric grid that extends outward from the vertex; (B) Double cone coil placed over the M1 
to measure single and paired pulse TMS. 
 
To measure short-interval cortical inhibition (SICI), paired-pulse TMS was used. Paired-pulse 
TMS was performed by delivering two pulses: a subthreshold conditioning stimulus (CS) 
followed by a suprathreshold test stimulus (TS), with an inter-pulse interval of 3ms. The CS 
was set at 80% of RMT, while the TS was set at 120% of RMT. By applying a subthreshold 
CS that preceded a suprathreshold TS, the CS activates inhibitory cortical neurons that 
suppresses the excitability of the TS, which provides a measure of cortical inhibition. A total 
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of 10 paired-pulse TMS was delivered and the resultant paired-pulsed MEP amplitude was 
expressed as a percentage of single-pulse MEP amplitude responses at 120% of RMT, whereby 
a lower percentage value indicated greater SICI. The equation that was used to calculate SICI 
was as follows: 
 
 
 
 
 
3.6 Sample size calculation and statistical analysis 
The sample size in this thesis was based on a sub-sample of participants from a larger RCT 
protocol paper published by Hendy et al. [211].  In this thesis, only 35 out of 42 participants 
proposed, were used for analyses and reporting of data.    
 
All statistical analyses were conducted using the statistical package for the social sciences 
(SPSS) v24 (IBM, New York, NY). To determine any differences in demographical and 
baseline data, a one-way analysis of variance (ANOVA) was used. A 3 x 4 analysis of variance 
(ANOVA) with factors TREATMENT (Ex + tDCS vs Ex + sham vs. Control) and TIME (0 
week vs. 3 weeks vs. 6 weeks vs. 9 weeks) was used to determine any effect of tDCS and PRT 
on measures of gait, balance, clinical outcome measures and corticospinal excitability and 
inhibition. Prior to repeated measures ANOVAs, the Kolmogorov-Smirnov test was first used 
to assess for normality in the data. Further, assumptions of sphericity were assessed using 
Mauchly’s test of sphericity. Where sphericity was violated, Greenhouse-Geisser estimates 
were used when epsilon was > .75. Alternatively, Huynh-Feldt estimates were used where 
epsilon was < .75. Tukey’s Honest Significant Difference (HSD) test was applied to determine 
SICI =  
Paired-pulse MEP amplitude 
Single-pulse MEP amplitude  
 X 100% 
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when and where significance was found. All figures and tables are presented as mean ± 
standard deviation (SD) and the significance threshold was set at  P < 0.05.. 
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CHAPTER 4 RESULTS 
4.1 Participant characteristics 
All participants that were involved in the project were comfortable with both TMS and a-
tDCS procedures. Those involved with the intervention had no issues performing the exercises 
and balance-specific activities. Of the 35 participants that were randomised into the Ex+Sham; 
Ex+tDCS; and Control groups, one participant withdrew from the Ex+Sham group, and one 
participant withdrew from the Ex+tDCS group before the intervention commenced 
(Participant recruitment and allocation are given in Figure 7. P. 50). Intervention compliance 
was 100% for all participants and no adverse events were reported during and after the 
intervention (Descriptive characteristics are given in Table 1. P. 47). 
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Figure 7: Flow diagram of recruitment, randomisation process and analysis. a-tDCS anodal 
transcranial direct current stimulation 
 
 
Control (n = 10) 
• Received allocated 
intervention (n = 10) 
• Did not receive 
allocated intervention 
(n = 0) 
Ex+tDCS (n = 13) 
• Received allocated 
intervention (n = 12) 
• Did not receive 
allocated intervention 
due to drop out of 
training (n = 0) 
Ex+Sham (n = 12) 
• Received allocated 
intervention (n = 12) 
• Did not receive 
allocated intervention 
due to drop out of 
training (n = 0) 
Assessed for  
eligibility (n = 400) 
Randomized 
 (n = 35) 
Excluded (n = 365) 
Not meeting inclusion criteria (n = 34) 
Declined to participate (n = 11) 
Other reasons (n = 320) 
Lost to follow-up (n = 0) 
Discontinued intervention 
due to medical concerns 
of diagnosis (n = 1) 
Lost to follow-up  
(n = 0) 
Discontinued intervention 
(n = 0) 
Lost to follow-up (n = 0) 
Discontinued intervention 
due to travel and distance 
to research facility (n = 1) 
Analysed (n = 11) 
Excluded from analysis 
due to limited 
measurements and data  
Analysed (n = 10) 
Excluded from analysis 
(n = 0) 
Analysed (n = 12) 
Excluded from analysis 
due to limited 
measurements and data 
Analysis Analysis 
Allocation Allocation 
Follow - Up Follow - Up 
Enrollment 
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Table 1 Demographical data of participants randomised into each group presented as mean ± SD 
Sample size (n) Age (Yrs) Sex(M/F) Weight (Kg) Height (Cm) MMSE (/30) Time Since Diagnosis (Yrs) 
Ex+Sham 11 70.63 ± 5.31 7M/4F 78.87 ± 10.59 170.0 ± 9.79 23.27 ± 1.61 4.31 ± 2.26 
Ex+tDCS 12 69.83 ± 6.65 10M/2F 78.36 ± 14.55 176.73 ± 10.79 23.25 ± 1.76 5.5 ± 3.78 
Control 10 71.80 ± 6.01 7M/3F 85.53 ± 19.73 174.41 ± 8.45 23.70 ± 1.88 4.85 ± 2.31 
MMSE – Mini mental state examination; SD – Standard deviation; Ex – Exercise; tDCS – transcranial direct current stimulation. 
Table 1 shows the demographic data of participants randomised into the three experimental group. No statistical differences were found in age 
(F1,32 = 0.745, P = 0.973), weight (F1,32 = 0.578, P = 0.951), height (F1,32 = 0.588, P = 0.913), MMSE score (F1,32 = 0.826, P = 0.943) and time since 
diagnosis (F1,32 = 0.745, P = 0.973) between all three experimental groups.  
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4.2 Step Length 
The changes in step length following single- and dual-task walking and dual-task cost across 
all experimental groups are shown in Figure 8. One-way ANOVA showed no between-group 
differences for baseline step length for the single-task (F1,32 = 0.632, P = 0.934) and dual-task 
(F1,32 = 0.546, P = 0.847) and for DTC (F1,32 = 0.849, P = 0.765). Mauchly’s test of sphericity 
further indicated that assumptions of sphericity was not violated for single (χ2 = 0.93, p = 
0.430) and dual-task (χ2 = 0.84, p = 0.213) step lengths and DTC (χ2 = 0.86, p = .232). 
Repeated measures ANOVA revealed no significant main effects (GROUP - F1,32 = 1.543, P 
= 0.177; TIME - F1,32 = 1.175, P = 0.383) or GROUP x TIME interaction (F1,32 = 0.994, P = 
0.416) in step length during the single-task walking condition. However significant main 
effects and interactions for dual-task walking (GROUP - F1,32 = 3.622, P = 0.024; TIME - F1,32 
= 3.114, P = 0.029; GROUP x TIME - F1,32 = 4.575, P = 0.013) and dual-task cost (GROUP - 
F1,32 = 3.721, P = 0.033; TIME - F1,32 = 7.744, P = 0.008; GROUP x TIME - F1,32 = 5.663, P 
= 0.005) were found. 
 
 
At 6 weeks (immediately post-intervention), a significant improvement in dual-task step length 
was observed in the Ex+Sham group compared to controls (12.9%, P = 0.032), while Ex+tDCS 
group showed significantly greater improvement in dual-task step length compared to the 
Control (23.7%, P = 0.012) and Ex+Sham (9.6%, P = 0.038) groups. At 9 weeks follow up, 
dual-task step length was still significantly greater in the Ex+Sham group compared to Controls 
(9.0%, P = 0.041), while the dual-task step length in the Ex+tDCS group was significantly 
greater than Control (17.4%, P = 0.021) and Ex+Sham (5.4%, P = 0.043) groups. When 
compared to Baseline values, only the Ex+tDCS group showed significant improvement in 
dual-task step length at 6 weeks (22.5%, P = 0.011) and 9 weeks (20.7%, P = 0.009). 
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In the context of this study, a reduction in dual-task cost indicates an improvement in gait 
performance during the dual-task condition. As a result of an improvement in dual-task step 
length in the Ex+Sham and Ex+tDCS groups, a significant reduction in dual-task cost in both 
groups compared to Controls was observed. Compared to the Control group, dual-task cost was 
reduced by 34.9% (P = 0.003) in the Ex+Sham group while the Ex+tDCS incurred 71.9% less 
cost (P < 0.001). Additionally, the dual-task cost for the Ex +tDCS group was 56.3% less (P 
< 0.001) compared to Ex+Sham. Compared to Baseline, only the Ex+tDCS group showed a 
significant reduction in dual-task cost at 6 weeks (-96.3%, P < 0.001) and 9 weeks (-66.4%, 
P< 0.001). 
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Figure 8. Changes in step length during single-task walking (A), dual-task walking (B) and 
dual-task cost (C) over 9 weeks for across all 3 experimental groups. (*) indicates significance 
of P < 0.05 from control; (+) indicates significance of P < 0.05 from Ex+Sham; (#) indicates 
significance P < 0.05 from Baseline.  
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4.3 Step Velocity 
The changes in step velocity following single- and dual-task walking and dual-task cost across 
all experimental groups are shown in Figure 9. One-way ANOVA showed no between-group 
differences for baseline step velocity for the single-task (F1,32 = 0.458, P = 0.953) and dual-
task (F1,32 = 0.575, P = 0.832) and for DTC (F1,32 = 0.812, P = 0.674). Mauchly’s test of 
sphericity further indicated that assumptions of sphericity was not violated for single (χ2 = 
0.78, P = 0.543) and dual-task (χ2 = 0.65, P = 0.334) step lengths and DTC (χ2 = 0.87, P = 
0.545). Repeated measures ANOVA revealed no significant main effects (GROUP - F1,32 = 
0.739, P = 0.537; TIME - F1,32 = 1.175, P = 0.383) or GROUP x TIME interaction (F1,32 = 
0.994, P = 0.416) in step velocity during the single-task walking condition. However 
significant main effects and interactions were observed for dual- task step velocity (F1,32 = 
2.741, P = 0.041; TIME F1,32 = 2.368, P = 0.044; GROUP x TIME - F1,32 = 3.110, P = 0.033) 
and dual-task cost (F1,32 = 2.134, P = 0.038; TIME F1,32 = 3.442, P = 0.037; GROUP x TIME 
- F1,32 = 4.761, P = 0.022). 
 
 
Over 3-, 6- and 9-week time-points, only the Ex+tDCS group showed a significant 
improvement from Baseline and compared to the other groups. Dual-task step velocity was 
21.8%, 22.1% and 23.3% greater (P < 0.05) at 3, 6 and 9 weeks respectively in the Ex+tDCS 
group compared to Baseline. Between-group comparisons further showed that dual-task step 
velocity in the Ex+tDCS group was significantly greater than Control and Ex+Sham groups 
at 3 weeks (Control 21.6%, Ex+Sham 26.2%; P < 0.05), 6 weeks (Control 22.2%, 
Ex+Sham 28.7%; P < 0.05) and 9 weeks (Control 19.6%, Ex+Sham 18.2%; P < 0.05). 
 
 
Similarly, dual-task cost was significantly reduced for the Ex+tDCS group 3, 6 and 9 weeks 
compared to Baseline and between groups. Compared to Baseline, dual-task cost for step 
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velocity was 32.6%, 37.4% and 32.9% less than Baseline (P < 0.05) with the Ex+tDCS group. 
Further, the dual-task cost for step velocity in the Ex+tDCS group was significantly less 
compared to Controls and Ex+Sham at 3 weeks (Control -39.6%, Ex+Sham -52.7%; P < 0.05), 
6 weeks (Control -57.3%, Ex+Sham -69.6%; P < 0.05) and 9 weeks (Control -55.8%, Ex+Sham 
-58.7%; P < 0.05). 
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Figure 9. Changes in step velocity during single-task walking (A), dual-task walking (B) and 
dual-task cost (C) over 9 weeks for across all 3 experimental groups. (*) indicates significance 
of P < 0.05 from control; (+) indicates significance of P < 0.05 from Ex+Sham; (#) indicates 
significance of P < 0.05 from Baseline.  
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4.4 Peripheral nerve and Corticospinal Excitability and Cortical Inhibition 
The changes in peripheral nerve excitability, corticospinal excitability and cortical inhibition 
are shown in Figure 10. One-way ANOVA showed no between-group differences at baseline 
for %MMAX (F1,32 = 0.765, P = 0.546), MEP amplitude (F1,32 = 0.844, P = 0.562) and SICI% 
(F1,32 = 0.86, P = 0.622). Mauchly’s test of sphericity further indicated that assumptions of 
sphericity was not violated for %MMAX (χ2 = 0.66, P = 0.653), MEP amplitude (χ2 = 0.65, P = 
0.334) and DTC (χ2 = 0.67, P = .643). Repeated measures ANOVA of MMAX amplitude showed 
a significant main effect for GROUP (F1,32 = 5.684, P = 0.013), but no effect for TIME (F1,32 = 
0.184, P = 0. 134) and GROUP x TIME interaction (F1,32 = 1.311, P = 0.374) was observed. 
No significant effects for neither GROUP (F1,32 = 0.856, P = 0.432), TIME (F1,32 = 0.967, P = 
0.344) nor GROUP x TIME interaction (F1,32 = 0.646, P = 0.421) were observed for MEP 
amplitude (%MMAX), while significant main effects for GROUP (F1,32 = 3.657, P = 0.026), 
TIME (F1,32 = 2.769, P = 0.031) and GROUP x TIME interaction (F1,32 = 3.455, P = 0.023) 
were observed for SICI. 
 
At 3 weeks, a significant increase in MMAX amplitude was observed in both the Ex+Sham 
(29.5%, P = 0.003) and Ex+tDCS (42.8%, P < 0.001) groups compared to Controls. Similarly 
at 9 weeks, MMAX amplitude was significantly greater in the Ex+Sham (42.7%, P < 0.001) and 
Ex+tDCS (29.5%, P < 0.001) groups relative to Controls.  
 
At 6 weeks, cortical inhibition was significantly reduced (as indicated by higher SICI%) in the 
Ex+tDCS group compared to Ex+Sham (-44.2%, P = 0.021) and Control (-36.8%, P = 0.036) 
group and to Baseline (-31.1%, P = 0.035). However at 9 weeks, a significant reduction in 
inhibition (as indicated by a greater SICI%) was observed with Ex+Sham compared to Controls 
(-43.6%, P < 0.001) and Baseline (-31.8%, P = 0.007). Similarly, a significant reduction in 
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SICI was observed with the Ex+tDCS group compared to Controls (-48.6%, P < 0.001) and to 
Baseline (-46.5%, P < 0.001). No significant differences were found between Ex+Sham and 
Ex+tDCS groups. 
 
 
61 
 
 
Figure 10. Measures of MMAX amplitude (A), MEP amplitude (B; % of MMAX) recorded at 
130% resting motor threshold and SICI (C) over 9 weeks for across all 3 experimental groups. 
For measures of SICI, a greater SICI% indicates lesser inhibition. (*) indicates significance of 
P<0.05 from control; (+) indicates significance of P<0.05 from Ex+Sham; (#) indicates 
significance of P < 0.05 from Baseline.  
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4.5 Clinical and Functional Outcome Measures 
Table 2. Clinical and functional outcome measures at each time point. All data are presented as Means ± SD. 
MDS-UPDRS-
III & IV 
TUG 
(sec) 
BBS FTSTST 
(sec) 
1RM- Quad 
(kg) 
1RM- Gas 
(kg) 
1RM- Ham 
(kg) 
1RM- TA 
(kg) 
Baseline 
Ex+Sham 25.72 ± 6.30 8.49 ± 2.98 52.62 ± 1.92 10.45 ± 2.41 154.63 ± 34.97 30.90 ± 9.64 25.36 ± 15.70 12.95 ± 3.96 
Ex+tDCS 30.41 ± 9.38 8.45 ± 2.05 53.0 ± 2.16 12.59 ± 4.47 151.0 ± 56.18 31.16 ± 7.96 28.08 ± 13.46 12.65 ± 3.15 
Control 34.0 ± 9.55 8.0 ± 1.54 52.80 ± 2.48 11.94 ± 4.92 159.50 ± 53.66 32.90 ± 6.13 28.0 ± 9.66 11.6 ± 2.75 
3 weeks 
Ex+Sham 21.50 ± 5.71 8.30 ± 2.66 53.57 ± 2.29 10.49 ± 3.23 176.40 ± 44.66 37.44 ± 7.31# 31.70 ± 17.20 14.62 ± 3.30 
Ex+tDCS 25.72 ± 6.16 7.86 ± 1.16 53.85 ± 2.19 11.54 ± 4.70 173.45 ± 61.42 39.88 ± 9.54# 34.72 ± 16.40 16.06 ± 3.14# 
Control 32.10 ± 9.75 8.80 ± 1.74 52.0 ± 3.01 12.14 ± 4.20 166.0 ± 50.59 29.90 ± 4.72 27.40 ± 9.20 11.67 ± 2.80 
6 weeks 
Ex+Sham 20.30 ± 6.78 7.87 ± 2.62 53.57 ± 2.22 9.45 ± 1.35 181.50 ± 45.09# 37.50 ± 6.72# 34.55 ± 21.47 15.94 ± 3.88 
Ex+tDCS 23.72 ± 5.97# 7.50 ± 0.95# 54.42 ± 1.61 10.67 ± 3.44 184.72 ± 72.30# 44.72 ± 3.23# 34.81 ± 13.97 17.48 ± 3.53# 
Control 30.70 ± 5.58 8.71 ± 1.46# 50.90 ± 3.84 13.35 ± 3.61# 167.50 ± 49.11 29.10 ± 3.24 38.60 ± 8.34 11.9 ± 2.89 
9 weeks 
Ex+Sham 22.50 ± 12.07 7.73 ± 3.08 53.42 ± 2.37 10.13 ± 2.36 177.70 ± 45.40# 35.70 ± 4.83# 31.40 ± 18.95 14.42 ± 3.88 
Ex+tDCS 24.0 ± 7.84# 7.56 ± 0.91# 53.42 ± 2.93 9.86 ± 4.38 179.09 ± 67.85# 39.27 ± 6.41# 33.09 ± 16.64 15.62 ± 3.08 
Control 32.40 ± 8.34 8.80 ± 1.43# 51.10 ± 3.34 14.98 ± 3.74# 158.0 ± 51.86 29.70 ± 3.09 38.60 ± 7.91 11.07 ± 2.69 
1RM – 1 repetition maximum; 10MWT – 10 metre Walking Test; BBS – Berg Balance Scale; Ex – Exercise; FTSTST – Five times sit-to-stand test; Gas – 
Gastrocnemius; Ham – Hamstring; MDS-UPDRS-III – Movement Disorder Society Unified Parkinson’s Disease motor subscale III; SD - Standard deviation; 
TA – Tibialis Anterior; TUG – Timed Up and Go; tDCS – Transcranial Direct Current Stimulation; Bold-face values represent significance of P < 0.05 from 
Control group; (#) represents significance of P < 0.05 from Baseline. The MDS-UPDRS and BBS results are measured using points rather than units. 
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All changes in clinical and functional outcome measures are shown on Table 2. One-way ANOVA 
showed no between-group differences at baseline for MDS-UPDRS-III & IV (F1,32 = 0.463, P = 0.563), 
TUG (F1,32 = 0.755, P = 0.768), BBS (F1,32 = 0.654, P = 0.355), FTSTST (F1,32 = 0.524, P = 0.475), 
1RM- Quad (F1,32 = 0.842, P = 0.612), 1RM- Gas (F1,32 = 0.776, P = 0.601), 1RM- HAM (F1,32 = 0.587, 
P = 0.768), 1RM- TA (F1,32 = 0.678, P = 0.556). Mauchly’s test of sphericity further indicated that 
assumptions of sphericity was not violated for MDS-UPDRS-III & IV (χ2 = 0.61, P = 0.311), TUG 
(χ2 = 0.76, P = 0.378, BBS (χ2 = 0.87, P = 0.234), FTSTST (χ2 = 0.78, P = 0.278), 1RM- Quad (χ2 = 
0.67, P = 0.333), 1RM- Gas (χ2 = 0.89, P = 0.154), 1RM- HAM (χ2 = 0.77, P = 0.256), 1RM- TA (χ2 
= 0.68, P = 0.345). 
 
For MDS-UPDRS-III & IV, significant main effects for GROUP and TIME for MDS-UPDRS-III & 
IV score (GROUP - F1,32 = 3.564, P = 0.033; TIME - F1,32 = 5.362, P = 0.014). MDS-UPDRS-III & IV 
scores (i.e. lower score indicates better functional outcome) were significantly lower in the Ex+Sham 
and Ex+tDCS groups compared to Control at 3 weeks (Ex+Sham -33.0%, Ex+tDCS -19.9%; P < 0.05), 
6 weeks (Ex+Sham -33.8%, Ex+tDCS -22.7%; P < 0.05) and at 9 weeks (Ex+Sham -30.6%, Ex+tDCS 
-25.9%; P < 0.05). Compared to Baseline, the Ex+tDCS group significantly improved (P < 0.05) by 
27.0% at 6 weeks and 21.1% by 9 weeks.  
 
For TUG, significant main effects for GROUP (F1,32 = 3.864, P = 0.039) and TIME (F1,32 = 3.564, P = 
0.033) were observed. At 6 weeks, the Ex+Sham and Ex+tDCS groups showed a significant 
improvement (P < 0.05) of 9.6% and 10.4% respectively from the Control group. By 9 weeks, these 
improvements were maintained at 12.2% and 14.1% in the Ex+Sham and Ex+tDCS groups 
respectively compared to the Control group. Additionally, the Ex+tDCS group saw a significant 
improvement from Baseline at 6 (11.2%) and 9 (10.7%) weeks, whereas a significant decrease (P < 
0.05) in TUG performance was observed at 6 (8.9%) and 9 (10%) weeks with the Control group.  
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For FTSTST, significant main effects for GROUP (F1,32 = 4.167, P = 0.027) and TIME (F1,32 = 2.564, 
P = 0.043) were observed. At 6 weeks, the Ex+Sham and Ex+tDCS groups showed a significant 
improvement (P < 0.05) of 28.6% and 20.1% respectively from the Control group. By 9 weeks, these 
improvements were maintained at 32.2% and 34.2% in the Ex+Sham and Ex+tDCS groups 
respectively compared to the Control group. Additionally, a significandecrease (P < 0.05) in FTSTST 
performance was observed at 6 (11.8%) and 9 (25.5%) weeks with the Control group was observed.  
 
For 1RM-Quad, significant main effects were observed for GROUP (F1,32 = 4.765, P = 0.013) and 
TIME (F1,32 = 5.239, P = 0.011). At 6 weeks, the Ex+Sham and Ex+tDCS groups showed a significant 
improvement (P < 0.05) of 8.3% and 10.3% respectively from the Control group. By 9 weeks, these 
improvements were maintained at 12.3% and 13.3% in the Ex+Sham and Ex+tDCS groups 
respectively compared to the Control group. Additionally, the Ex+Sham and Ex+tDCS groups saw a 
significant improvement (P < 0.05) from Baseline when compared to 6 weeks (Ex+Sham 17.3%; 
Ex+tDCS 22.3%) and 9 weeks (Ex+Sham 11.4%; Ex+tDCS 12.3%).  
 
For 1RM-Gas, significant main effects were observed for GROUP (F1,32 = 3.889, P = 0.028) and TIME 
(F1,32 = 3.854, P = 0.028). 1RM-Gas strength was significantly increased in the Ex+Sham and 
Ex+tDCS groups compared to Control at 3 weeks (Ex+Sham 25.2%, Ex+tDCS 33.4%; P < 0.05), 6 
weeks (Ex+Sham 28.9%, Ex+tDCS 53.7%; P < 0.05) and 9 weeks (Ex+Sham 20.2%, Ex+tDCS 
32.2%; P < 0.05). Additionally when compared to Baseline, 1RM-Gas strength was improved 
significantly at 3 weeks (Ex+Sham 21.2%, Ex+tDCS 28.0%; P < 0.05), 6 weeks (Ex+Sham 21.3%, 
Ex+tDCS 43.5%; P < 0.05) and 9 weeks (Ex+Sham 15.5%, Ex+tDCS 26.0%; P < 0.05) in both the 
Ex+Sham and Ex+tDCS groups.  
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For 1RM-TA, significant main effects were observed for GROUP (F1,32 = 3.116, P = 0.036) and TIME 
(F1,32 = 3.176, P = 0.026). At 3 weeks, an improvement in 1RM-TA strength was only observed in the 
Ex+tDCS group compared to the Control group (37.6%, P < 0.05) and to Baseline (27.0%, P < 0.05). 
However at 6 weeks, both Ex+Sham and Ex+tDCS groups showed significant improvements in 1RM-
TA strength of 33.9% and 46.9% (both P < 0.05) respectively compared to the Control group, and 
23.1% and 38.2% respectively compared to Baseline. At 9 weeks, the Ex+Sham and Ex+tDCS groups 
showed significant improvements in 1RM-TA strength of 30.2% and 41.1% compared to Controls. 
 
No significant differences were observed between the Ex+Sham and Ex+tDCS groups in all clinical 
and functional outcome measures.  
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CHAPTER 5 DISCUSSION 
5.1 Discussion Summary 
The results from this thesis provide evidence of how functional exercise modalities with the additional 
application of a non-invasive neuro-modulatory tool can improve muscular strength, gait dynamics, 
and facilitate neuroplastic changes in the M1 for people with PD. This thesis shows how PRT and 
balance-specific training; alone, improves measures of gait for efficient and coordinated movements.  
The results further shows how the additional application of tDCS in combination with progressive 
resistance and balance-specific training (PRBT) contribute to the induced changes in SICI and the 
modulation of inhibitory circuits.  It also supports evidence on how both exercise modalities in 
combination with tDCS relative to the 9 week follow up exhibit a prolonging effect in strength, gait, 
and neuroplastic changes. Furthermore, this thesis will provide an overview on how each measure 
contributes to the findings for the use of non-invasive brain stimulation, PRT of the lower limbs, and 
balance-specific training as a therapeutic application for people with PD. 
 
The main findings from this thesis indicated a significant improvement in dual-task step length 
and cost in the Ex+Sham and an even greater improvement in the Ex+tDCS compared to Control 
at 6 and 9 weeks. However the improvements in dual-task step velocity was observed only in the 
Ex+tDCS group at 3, 6 and 9 weeks compared to Ex+Sham, Controls and to Baseline. The 
secondary findings of this thesis showed that peripheral muscle excitability was improved across 
all time points in both experimental groups that received PRBT, however no differences in 
corticospinal excitability were observed between PRBT groups and across time when measuring 
MEP amplitude at 130% RMT. Interestingly, Ex+tDCS elicited a significant reduction in cortical 
inhibition at 6 and 9 weeks compared to both Ex+Sham and Control, whereas cortical inhibition 
was only significantly reduced in the Ex+Sham group at 9 weeks 
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compared to Control. For clinical and lower limb measures, both experimental groups 
elicited a significant improvement to MDS-UPDRS-III & IV, TUG, FTSTST and 1RM- 
QUAD/GAS/TA that were observed at 3, 6 and 9 weeks compared to Control, however 
no differences were observed between Ex+Sham and Ex+tDCS. Based on the findings 
from this thesis, it may be suggested that PRBT concurrent with balance-specific training 
is beneficial for improving measures of functional and gait performance, peripheral nerve 
excitability and cortical inhibition. The inclusion of a-tDCS concurrent with PRBT 
further improved dual- task cost of step length and velocity, and cortical inhibition. This 
discussion will provide an overview on how each measure contributed to the support for 
the use on non-invasive brain stimulation, PRBT of the lower limbs, and balance-specific 
training as a therapeutic application for people with PD. 
 
5.2 Research Question 1 - Could a 6-week lower limb PRT concurrent with balance-
specific training increase step length, step velocity, corticospinal excitability/inhibition 
and clinical and functional outcome measures in people with PD? 
 
The first aim of this thesis was to determine if 6 weeks of combined PRT and balance-specific 
training would improve measures of gait performance, neurophysiological function, clinical 
and lower limb functional measures in people with mild-to-moderate PD. The findings from 
this thesis suggest that the PRT intervention was efficacious in eliciting improvements to dual-
task step length, MDS-UPDRS-III & IV and lower limb functional measures such as the TUG, 
FTSTST and 1RM strength of the QUAD, GAS and TA.  
 
The results from this thesis were partially in line with previous studies that have used PRT as 
a training modality in PD. In particular, seminal studies by Hirsch et al. [220], used a 
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combination of high-intensity PRT with balance-specific training and showed a significant 
improvement in leg strength compared to controls that only performed balance training. The 
findings from Hirsch and colleagues were further supported by Schilling et al. [13], which 
showed an improvement in leg press strength, but not in functional measures such as the TUG 
and 6-minute walk test following 8 weeks of strength training compared to usual care alone. 
Indeed, recent systematic review and meta-analyses [209, 221] including one from this thesis 
[118], showed that strength training alone improved lower limb strength, but not other 
functional measures of gait and balance. This prompted the development of the current exercise 
program used in this study whereby PRT training was interspersed with dynamic balance-
specific training to target gait and functional performance of the lower limbs.  
 
In addition to improvements in 1RM strength of the lower limbs, the results showed a 
significant improvement in the MDS-UPDRS-III & IV and in functional measures such as the 
TUG and FTSTST, but not the BBS. The MDS-UPDRS-III & IV is a gold-standard clinical 
measure of upper and lower limb fine and gross motor coordination. Specifically, the MDS-
UPDRS-III & IV provides a quantification of dyskinesias commonly observed in PD such as 
bradykinesia (slowness in movement) and hypokinesia (partial or complete loss of movement). 
In this study, the MDS-UPDRS-III scores were significantly improved at 3, 6 and 9 weeks in 
both Ex+Sham and Ex+tDCS groups. As with bradykinesia and hypokinesia, the 
pathophysiological underpinnings of both symptoms are related to dopaminergic deficits, 
which results in a reduction in excitatory drive to the M1 that may disrupt cortical activation 
of the muscle [222, 223]. While not directly measured in this study, it is likely that the PRBT 
intervention may have led to an increase in endogenous striatal DA release [22, 224], which 
may improve MDS-UPDRS-III & IV scores. Further, there is evidence from a 24-month 
randomised controlled trial to suggest that PRT improves agonist-antagonist muscle activity 
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which leads to improved motor control [119]. While this study was only 6 weeks in duration, 
it may be plausible that these neurophysiological adaptations might be a factor for improved 
UPDRS-III & IV scores, considering that the PD participants were only mild-to-moderate in 
severity in this study.   
 
The improvements observed in the TUG and FTSTST were expected. Considering that both 
tests required muscle strength and power, an improvement in overall muscle strength would 
have likely underpinned an improvement in both the TUG and FTSTST as well. Similarly, the 
improvements shown in the TUG test does indicate a close relationship in balance control while 
in motion.  Contemporary to the improvements in step length and step velocity, muscle 
strengthening warrants spatial distribution during movement, which can also suggest an 
interaction of dynamic sensorimotor improvement Based on studies in elderly adults, 
improvements to TUG and FTSTST with PRT interventions have been commonly reported. 
For example, Fiatarone et al. [225], studied the adaptations induced by resistance training in 
100 frail elderly men and women. The subjects underwent resistance training that consisted of 
3 sets of 8 repetitions at 80% of 1RM, 3 times per week for 10 weeks. The results revealed that 
the resistance training groups improved their habitual gait velocities and functional abilities 
such as stair-climbing, TUG and FTSTST. These improvements were concomitant with 
improved leg muscle strength outcomes. In another study, Lustosa et al. [226], observed 
significant improvements in TUG, gait speed and power in pre-frail elderly subjects (72 ± 4 
years) after 12 weeks of PRT (3 times per week). In this study, a half-squat exercise was 
performed using the participants' body weights as resistance. Indeed, measures from peripheral 
nerve stimulation showed an increased state of motor-neuronal excitability that is likely to 
contribute to the improvements in functional measures as seen in the experimental groups.  
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Interestingly, while a large focus of this study was targeted at improving balance, no 
improvements in the BBS were observed in either of the experimental groups. At this stage, it 
is unclear as to why no improvements were observed. However as the BBS involves a variety 
of static balance tests, it may be that the BBS was insensitive to dynamic balance for which 
most of our balance exercises were designed for. Further, it is also plausible that the balance 
exercises conducted in this intervention were solely in concurrent with muscle strengthening 
in a controlled environment, rather than in a more functional setting that mimics daily life 
activities.    
 
Another interesting finding from this thesis was that there were no improvements in single-task 
step length and velocity, however dual-task step length was improved compared to Control 
following 6 weeks of Ex+Sham, which was maintained even at 9 weeks. The aim of using a 
dual-task design in this study was to provide an index of central cognitive processing during 
gait. In PD, studies have shown that people with PD exhibit greater deficits in gait performance 
(i.e. stride length and cadence) during dual-task gait compared to healthy controls that is due 
to reduced executive functioning and increased attentional demands associated with the disease 
[227, 228]. While the aim of this study was not to evaluate the effects of PRBT on cognitive 
performance, it is postulated that an improvement in dual-task step length and cost observed at 
6 and 9 weeks was likely due to an improved ability to process greater cognitive and motor 
attentional demands. Alternatively, the improvement in functional ability may lead to a 
decrease the cognitive demands during gait performance.   
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5.3 Research Question 2 - Would the application of a-tDCS over the M1 concurrent with 
PRT, and balance-specific training further increase measures of step length, step velocity, 
corticospinal excitability/inhibition and clinical and functional outcome measures in 
people with PD?  
 
The main findings from this thesis showed that the addition of anodal tDCS (a-tDCS) improved 
dual-task step length and velocity, and cost for both these measures. Additionally, a-tDCS 
elicited a release of cortical inhibition at 6 and 9 weeks compared to Ex+Sham (only at 9 
weeks).  
 
Transcranial direct current stimulation has been shown to induce polarity-specific modulation 
of corticospinal excitability and inhibition, which has been proposed to facilitate 
neuroplasticity and learning [165]. Several previous studies have applied a-tDCS concurrent to 
physical therapy to improve motor function such as stroke [229], and traumatic brain injury 
[159].  In PD, several recent pilot randomised controlled trials have been published with mixed 
results [230]. The findings from our thesis support the role of a-tDCS in eliciting further 
improvements to dual-task performance and cortical inhibition, however  the findings from this 
thesis further suggest that it was not efficacious in eliciting greater improvements to clinical 
and functional measures compared to Ex+Sham. In line with findings from Yotnuengnit et al. 
[230], Schabrun et al. [165], and Costa-Ribeiro et al. [159], the addition of a-tDCS to physical 
therapy (i.e. gait, balance or in this study a combination of resistance and balance training) did 
not result in greater enhancement of clinical and lower limb functional measures. It is 
postulated that the intensity associated with PRT alone was significant to induce functional 
improvements that would potentially overshadow any effects of a-tDCS. Moreover, due to a 
potential ceiling effect, the mechanism of a-tDCS was more likely targeted at retention and 
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consolidation rather than improvement of physical and motor function. Indeed, previous 
studies combining both tDCS and physical therapy in PD and stroke have shown that rather 
than an improvement in physical function following therapy, a longer-term retention of 
physical function was observed 3-8 weeks after therapy was completed [159]. 
 
While the improvements in clinical and lower limb functional measures were not facilitated by 
a-tDCS, the findings from this thesis supported the role of a-tDCS in enhancing dual-tasking 
abilities, specifically step length and velocity, compared to Ex+Sham. This potentially 
indicates that the inclusion of a-tDCS may have enhanced synaptic efficacy [231] to allow for 
greater attentional motor and cognitive demands to be processed. Indeed, a pilot study by 
Schabrun et al. [165] suggested that while no enhancements in dual-task gait performance 
during the TUG were observed (following 3 weeks of dual-task gait training vs. dual-task gait 
training and a-tDCS), backwards counting response during the TUG was significantly more 
accurate in the a-tDCS and dual-task gait training group when applied to the M1. More 
importantly, this enhancement in dual-task performance was observed at 3 weeks lasting up to 
9 weeks, which was greater than either the Control or Ex+Sham groups.  
 
An interesting observation that was found only within the Ex+tDCS group was the reduction 
in SICI immediately following PRBT that was maintained at 9 weeks, while SICI within the 
Ex+Sham was only observed at 9 weeks. Previously, the modulation of SICI has been 
postulated to be involved in the process of motor skill acquisition and retention that have been 
observed following a period of motor training, particular those at higher intensities or increased 
sensorimotor demands [232, 233]. Specifically, the training-induced reduction in SICI from 
pre- to post-training seems to suggest that the reduction of SICI may be associated with 
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improvement in motor performance and may be a key mechanism underpinning use-dependent 
neuroplasticity [234]. Additionally, previous studies combining the use of a-tDCS during 
strength training of the upper limb have shown to reduce SICI compared to strength training 
alone [210, 235], which suggest a complementary effect of a-tDCS and motor training to 
augment processes underpinning use-dependent neuroplasticity. Indeed, this combined effect 
of a-tDCS and motor training on SICI have been observed not only in healthy populations, but 
also in clinical populations such as stroke [236, 237] and healthy older adults [39].  It may be 
that the priming effect of a-tDCS may have facilitated the release of cortical inhibition that was 
induced by PRBT. In this study, it was observed that dual-task step length, velocity and dual-
task cost (for both step length and velocity) were improved concomitant with a reduction in 
SICI only with Ex+tDCS at 6 and 9 weeks. While it cannot be certain if there was direct 
relationship between reduction in SICI and improvements in gait parameters, these results are 
in agreement with previous studies indicating a reduction in SICI following the combination 
of a-tDCS and motor training. Interestingly, a reduction in SICI was also observed with in the 
Ex+Sham group at 9 weeks. While it is uncertain at this stage why SICI was only reduced 3 
weeks after PRBT, a study by Weier et al. [238], previously showed that SICI was significantly 
reduced following lower limb strength training, which the authors suggested that high-intensity 
strength training may provide neuroplasticity-like changes akin to leaning a novel/complex 
motor task. The delayed SICI response shown in the current study may therefore reflect a form 
of acute memory consolidation associated with impaired neuroplasticity in PD.   
5.4 Limitations and future directions 
While the current data in this thesis provided evidence for the role of PRBT and a-tDCS in 
improving measures of gait and lower limb function, certain limitations need to be 
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acknowledged that may have contributed to some of the findings in this thesis. Firstly, it is 
acknowledged that the sample size was similar to previous studies in PD and older adults with 
movement disorders. It is likely that a larger sample size will provide more robust evidence for 
measures that did not reach significance. The small sample size may also speak to the lack of 
significant findings for our gait and TMS measures, which inherently has a large variability in 
inter-individual response [239]. In addition, due to the small sample size the lack of statistical 
evidence to illustrate the distribution of disease severity for participants is likely to be 
underpowered, and unable to detect any differences in H&Y scores between each group. 
Furthermore, as the H&Y scale is categorical data (scored 1-5), it has been implemented to 
ensure that there is minimal difference in disease severity between each experimental group.  
From a clinical and functional perspective, the participants involved in this thesis fell between 
the score of 2 and 3, limiting factors for those that account with a lower H&Y score (i.e. low 
disease burden). However, this limitation will be factored into our analysis for future 
publications to account for any potential between-group differences.  Another limitation of this 
study was the lack of cognitive measures to better substantiate our hypothesis that PRBT and 
a-tDCS enhanced cortical processing during the dual-task gait performance. Future studies 
could potentially include neuroimaging modalities such as electroencephalography during gait 
to quantify any changes in cortical activation associated with PRBT and a-tDCS. Finally, an 
increase in gait performance, and corticospinal excitability and inhibition was indicative 
through the combination of a 6 week exercise, balance-specific and neuro-modulatory 
intervention.  Perhaps, implementing a longer intervention consisting of the previous measures 
could increase a more favourable significance in the outcome measures. The findings from this 
thesis further provide promising pilot results to support the combination of PRBT and a-tDCS 
in neuro-rehabilitation, particularly in populations (e.g. ageing and PD) that are at risk of 
postural instability and gait disturbances. While, the clinical utility and application of PRBT 
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and a-tDCS remains to be seen, the portable, inexpensive nature and ease-of-application of 
tDCS devices may provide complementary benefits to gait rehabilitation within a clinical 
setting. Future studies could also consider the pragmatic application of tDCS and PRBT within 
a clinical setting to determine clinical efficacy and safety guidelines for different clinical 
populations.  
5.5 Summary 
Overall, the findings from this thesis support the role of PRBT in improving lower limb function 
and dual-task gait performance in people with mild-to-moderate PD. These improvements in 
function are likely to be underpinned improvement to peripheral muscle function and 
potentially intracortical mechanisms such as SICI. Additionally, while the inclusion of a-tDCS 
to PRBT did not further enhance single-task gait performance and lower limb function, dual-
task gait performance was significantly improved during the first stages of the intervention and 
demonstrated retaining effect in performance at 9 weeks follow up. These findings therefore 
provide evidence for the role of a-tDCS in facilitating central attentional processes to cope with 
the additional motor and cognitive demands associated with dual-task paradigms. Due to 
previously described ceiling effect, a fundamental consideration for future research would 
consider applying a-tDCS to the PFC given that its outcome on motor aspects was limited. It 
is also noteworthy to mention that the length of treatment as well as the duration of each 
stimulation session needs to be considered in regards to identifying motor and functional 
performance.  
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The use of progressive resistance training (PRT) to improve gait and balance in people with
Parkinson’s disease (PD) is an emerging area of interest. However, the main effects of PRT
on lower limb functions such as gait, balance, and leg strength in people with PD remain
unclear. Therefore, the aim of the meta-analysis is to evaluate the evidence surrounding
the use of PRT to improve gait and balance in people with PD. Five electronic databases,
from inception to December 2014, were searched to identify the relevant studies. Data
extraction was performed by two independent reviewers and methodological quality was
assessed using the PEDro scale. Standardized mean differences (SMD) and 95% confi-
dence intervals (CIs) of fixed and random effects models were used to calculate the effect
sizes between experimental and control groups and I2 statistics were used to determine
levels of heterogeneity. In total, seven studies were identified consisting of 172 partici-
pants (experimental n=84; control n=88). The pooled results showed a moderate but
significant effect of PRT on leg strength (SMD 1.42, 95% CI 0.464–2.376); however, no
significant effects were observed for gait speed (SMD 0.418, 95% CI −0.219 to 1.055).
No significant effects were observed for balance measures included in this review. In con-
clusion, our results showed no discernable effect of PRT on gait and balance measures,
although this is likely due to the lack of studies available. It may be suggested that PRT be
performed in conjunction with balance or task-specific functional training to elicit greater
lower limb functional benefits in people with PD.
Keywords: Parkinson’s disease, progressive resistance training, leg strength, gait speed, balance
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative move-
ment disorder, which stems primarily from the death of dopamin-
ergic (DA) neurons in the basal ganglia circuitry, and is character-
ized by motor abnormalities such as resting tremors, bradykinesia,
rigidity, and postural instability (Hornykiewicz and Kish, 1987;
Yoritaka et al., 2013). In addition to motor deficits, people with
PD often experience non-motor impairments such as cognitive,
neuropsychiatric, sleep, autonomic and sensory disturbances that
results in a reduced quality-of-life (Chaudhuri et al., 2006; Park
and Stacy, 2009). It has been estimated that approximately 7
million people suffer from PD worldwide and these figures are
expected to increase as the average age of the population increases
(Kasten et al., 2007).
Due to the neurological impairments associated with PD, cou-
pled with age-related musculoskeletal declines, people diagnosed
with PD are at greatest risk of falls with several studies reporting
38–87% of all people with PD experiencing severe falls at least
once in their lifetime (Ashburn et al., 2001; Balash et al., 2005). A
meta-analysis of several prospective studies further showed that
the rate of recurrent falling over a 3-month period was 57%
among people with PD who had reported previous falls (Picker-
ing et al., 2007). Given the severity and chronic nature of PD, DA
medications are often initiated during the early stages of the dis-
ease and continue to be prescribed throughout their lives (Stowe
et al., 2008; Grosset et al., 2010). However, it is estimated that
the annual medical cost associated with PD is between $10,043
and $12,491 (Noyes et al., 2006; Boland and Stacy, 2012) and
the long-term use of DA medication is not without side-effects,
which may include addiction, behavioral disturbances (Merims
and Giladi, 2008), and levodopa-induced dyskinesia (Bezard et al.,
2001). More importantly, studies have shown that the underlying
mechanisms of postural instability and gait difficulties in PD are
dopamine-resistant (Bloem et al., 1996; Bohnen and Cham, 2006),
which may explain the greater fall rate in people with PD (Johnson
et al., 2013).
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In recent years, the use of exercise to improve motor symptoms
in PD has received great interest. Several meta-analyses investi-
gating the effects of aerobic exercise interventions such as tread-
mill walking reported significant improvements to gait, balance,
and cardiovascular fitness in people with moderate-to-severe PD
(Goodwin et al., 2008; Shu et al., 2014). In particular, several stud-
ies have also reported beneficial effects on motor function, muscle
strength, and endurance following progressive resistance training
(PRT) (Brienesse and Emerson, 2013; Lima et al., 2013). Recently,
Corcos et al. (2013) conducted a large randomized controlled trial
investigating the effects of a 24-month whole-body PRT inter-
vention in 38 PD participants and showed a clinically significant
improvement in off-medication unified Parkinson’s disease rating
scale (UPDRS) scores. Although it is unclear as to what mecha-
nisms underpin the improvements in motor symptoms following
PRT, several studies suggest that PRT may help to improve muscle
strength and mass (Hirsch et al., 2003; Dibble et al., 2006, 2009),
and normalize neuroplasticity that may otherwise be impaired in
people with PD (Teo et al., 2014).
Despite the evidence supporting the use of PRT to improve clin-
ical measures of motor function, little is known about the effects
of PRT on gait and balance measures in people with PD. Several
meta-analyses conducted on the effects of PRT on gait and bal-
ance measures in healthy aging population showed inconsistent
findings due to the wide disparity in the type of measures used
(Latham et al., 2004; Orr et al., 2008; Steib et al., 2010). However,
preliminary studies in people with mild-to-moderate PD found
that high-intensity eccentric lower limb resistance training on a
cycle ergometer resulted in increased muscle size in the quadriceps
muscle, which correlated to improvements in lower limb muscle
force and measures of mobility (Dibble et al., 2006, 2009). How-
ever, it is unclear if PRT alone is able to elicit improvements to
balance and gait in people with PD. To the best of our knowledge,
only one other meta-analysis conducted by Lima et al. (2013) indi-
cated that PRT is beneficial for improving leg strength and physical
function in people with PD that is not limited to just gait and bal-
ance. Therefore, this meta-analysis aims to evaluate the current
literature for evidence to support the functional benefits of PRT
on gait and balance in people with PD and to identify critical gaps
in the literature that needs to be addressed in future research.
METHODS
SEARCH STRATEGY
This review has been informed by the PRISMA statement (Moher
et al., 2009). The following electronic databases were searched
from their inception to December 2014: PubMed, MEDLINE,
PsycINFO, Embase, and Scopus. The following keywords were
used in combinations: Parkinson, Parkinson’s disease, Parkinson-
ism, resistance training, strength training, exercise, gait, balance,
and physical therapy. Figure 1 shows a flow diagram of the pro-
cessing of search results from initial searches to the final included
studies.
SELECTION CRITERIA
Studies were included if (1) the aim of the study was to exam-
ine the effects of PRT on gait and balance in PD; (2) the target
population was aged between 20 and 85 years with a confirmed
diagnosis of PD; (3) the main intervention was PRT and the exer-
cises specifically targeted the lower limb; (4) the effects of the
resistance exercise intervention were compared to other training
intervention, including other forms of exercise or physical activ-
ity; (4) the outcomes included either balance, gait, or leg strength.
A study was excluded if (1) the effects of other forms of exercise
not involving PRT were evaluated (such as behavioral interven-
tions, music therapy, cueing strategies, or whole body vibration);
(2) does not have a control group; (3) it was not randomized.
Data was extracted by two independent reviewers (Alex Tillman
and Wei-Peng Teo) and is summarized in Table 1. To determine the
eligibility of each study, the title and abstract was screened inde-
pendently, and if the title and abstract did not meet the inclusion
criteria, it was excluded. Only full-text articles that were obtainable
were used and if the article did not report the relevant informa-
tion, the corresponding authors were contacted. Further eligibility
screening was then independently conducted for these articles by
two reviewers (Alex Tillman and Ashlee M. Hendy), by using a
standardized form containing the details of the inclusion criteria.
For crossover studies, only the results from the first phase of the
study were used to prevent any biased implications when inter-
preting the results. Any discrepancies were resolved by consensus
with reference to the original article.
QUALITY ASSESSMENT OF STUDIES
For each article, one reviewer (Alex Tillman) extracted all the data
and a second reviewer (Wei-Peng Teo) performed a secondary
check on the extracted data set. Any discrepancies found were
resolved by discussion and care was taken to identify duplicate
reports of any articles found. Only published articles that include
articles in press were included in the meta-analysis. The method-
ological quality of each study was assessed independently by two
reviewers (Dawson J. Kidgell and Timo Rantalainen) separate from
the data extraction phase using the physiotherapy evidence data-
base (PEDro) scale (ranging from 0–10 points). The PEDro scale
is an assessment tool for evaluating methodological quality of ran-
domized control trials conducted in the field of physiotherapy and
has been previously shown to have fair-to-good reliability (Maher
et al., 2003; Macedo et al., 2010). A cut-off point of 6 on the
PEDro scale was used to indicate high-quality studies (Macedo
et al., 2010). Any disagreements in scores were resolved by discus-
sion between reviewers, with the judgment of the primary author
(Wei-Peng Teo) being sought if necessary. All scores assigned to
each study were agreed upon by consensus and are presented in
Table 2.
SELECTION OF OUTCOME MEASURES
The outcome measures for balance, gait speed, and leg strength
used in the meta-analysis were selected based on their ability to
provide direct quantitative measures or confidence scores. Clinical
outcome measures such as the 6min and 10 m walking tests were
used to provide a measure of gait speed. Additionally, studies using
biomechanical analysis such as the Walkway and 3-dimensional
motion capture system that provided a quantitative measure of
gait speed were also included. Balance is a subjective measure and
can be quantified in several ways. Studies that include direct pos-
turographic measures using forceplates. Swaymeters attached to
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FIGURE 1 | PRISMA flow chart for the selection of studies included in this meta-analysis.
the participant’s waist or sensory orientation tests were included
into our meta-analysis; however, studies that provided confident
scores of balance during activity-specific tasks were also included.
Lastly, outcome measures that provided a direct measure of leg
strength in Newtons or kilograms such as 1-repetition maximum
leg presses, force dynamometers or strain gages attached to the
lower limb were included into the meta-analysis.
DATA SYNTHESIS AND ANALYSIS
Random effects meta-analyses were conducted with MedCalc
Statistical Software v14.12.0 (MedCalc Software bvba, Ostend,
Belgium; http://www.medcalc.org; 2014). Hedges’ g was used to
measure the effect sizes for all meta-analyses and presented as stan-
dardized mean difference (SMD) and 95% confidence intervals
(CI). Heterogeneity across studies was tested based on I 2 statistics.
Studies with I 2 <40% was considered to have low heterogene-
ity, I 2= 40–75% was considered moderate heterogeneity, and I 2
>75% was considered to have high heterogeneity. Fisher’s method
of combining p-values was applied to test for overall pooled effects
for each outcome measure.
RESULTS
STUDY SELECTION
Our initial search yielded 359 references. Following screening of
the title and abstract and removal of duplicates, nine studies were
further screened. After assessments against our inclusion criteria,
two studies were removed and seven studies were kept for further
analyses (Figure 1).
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Table 1 | Characteristics of studies of PRT in people with PD.
Study Sample size,
mean age
(years)
Hoehn
andYahr
stage
Mean
duration
of PD
(years)
Intervention
duration
(weeks)
Main outcome
assessments
Intervention group Control
group
Shulman
et al.
(2013), US
n=67; 65.8
(SD 10.7)
1–3 6.2 (SD 3.8) 16 • Gait speed Lower limb resistance training (2 sets×10 repetitions) Treadmill
training• Cardiovascular fitness • Leg presses
• muscle strength • Leg extensions
• UPDRS • Leg curls
Hass et al.
(2012), US
n=18; 65.5
(SD 2.1)
1–3 8.7 (SD 3.3) 10 • COP displacement
• Gait initiation
• Stride length and velocity
Lower limb resistance training (2 sets×10–12 repetitions) No
intervention• Seated leg presses
• Seated knee extension
• Seated knee flexion
• Abdominal curls
• Back extension
• Seated calf raises
• Multi-directional seat ankle movements with theraband
Allen et al.
(2010), AU
n=48; 67
(SD 1.4)
NR 8 (SD 1.4) 24 • UPDRS
• PDQ-39
• Strength
• Balance
• Freezing
• Postural sway
PRT (40–60 min) No
intervention• High stepping on the spot
• Standing with a decreased base
• Graded reaching in standing
• Stepping in different directions
• Walking
• Sit-to-stand
• Heel raises
• Lateral step-up
• Forward step-up
• Half-squats sliding down a wall
Balance training (10 s×15 reps each leg)
• Standing on one leg
Schilling
et al. (2010),
US
n=18; 59.1
(SD 3.0)
1–2.5 NR 8 • Strength
• Gait function
• ABC
Lower limb resistance training (3 sets×5–8 repetitions)
• Leg press
• Leg curl
• Calf press
Standard
exercise
management
of PD.
(Continued)
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Table 1 | Continued
Study Sample size,
mean age
(years)
Hoehn
andYahr
stage
Mean
duration
of PD
(years)
Intervention
duration
(weeks)
Main outcome
assessments
Intervention group Control
group
Dibble et al.
(2009), US
n=19; 65.6
(SD 1.9)
2.5 6.3 (SD 0.2) 12 • Muscle force production
• Quality of life
• UPDRS
• Gait speed
• PDQ-39
Lower limb and upper limb resistance training (45–60 min,
3 days/week)
Standard
exercise
management
of PD.
• Stretching
• Walking (treadmill)
• Riding (cycle ergometer)
• Machine and free weights (upper extremities)
Muscle force (3 sets×50–75% of perceived maximal effort)
• 60° seated fixed knee flexion
Dibble et al.
(2006), US
n=19; 65.6
(SD 1.9)
2.5 6.3 (SD 0.2) 12 • Muscle endurance Lower limb resistance training (45–60 min 3 days/week) Standard
exercise
management
of PD.
• Flexibility • Light calisthenics and stretching
• Balance • Walking (treadmill)
• Muscle production • Riding (cycle ergometer)
• UPDRS • Lifting weights (machine and free weights)
Hirsch et al.
(2003), US
n=15; 73.2
(SD 3.4)
1–2 6.9 (SD 1.9) 10 • Balance
• Muscle strength
Lower limb resistance training (60% 4-RM, 1 set×12 repetitions) No
intervention• Moving legs simultaneously at 6–9 s pre repetition
Lower limb muscle strength (standardized weight-and-pulley
system, 4-RM, 1 set×4 repetitions)
• Knee extension
• Knee flexion
• Ankle plantarflexion
Balance training (computerized dynamic posturograph)
• Sensory orientation test
NR, not reported; PRT, progressive resistance training;TBE, traditional balance training; COMBI, combination of both; UPDRS, unified Parkinson’s disease rating scale; GI, gait initiation; COP, center-of-pressure; PD,
Parkinson’s disease; ABC, activities-specific balance confidence; PDQ-39, Parkinson’s disease questionnaire 39.
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PARTICIPANT CHARACTERISTICS
In total, 172 people with PD were assessed across seven studies. The
mean age for all participants was 66± 3.5 years, while the mean
duration of PD was 7.1± 1.8 years. All seven studies recruited par-
ticipants with mild-to-moderate motor disabilities as identified by
the Hoehn & Yahr scale of 1–3.
METHODOLOGICAL QUALITY
Table 2 highlights the scores for each criterion using the PEDro
scale. It was determined that the average score for all seven trials
was five (lowest four, highest eight). Across the seven studies used,
it was found that all participants and therapists administering the
program were not blinded to the treatment of participants. Only
one study concealed the allocation of all participants, used blinded
assessors, and employed intention-to-treat analysis (Allen et al.,
2010).
GAIT SPEED
A total of six out of seven studies reviewed presented quantita-
tive measures of gait speed (Figure 2). The effects of PRT on gait
Table 2 | PEDro scale of quality for eligible randomized controlled trials.
Study Random
allocation
Concealed
allocation
Similar at
baseline
Subjects
blinded
Therapists
blinded
Assessors
blinded
<15%
Dropouts
Intention-
to-treat
analysis
Between-
group
comparisons
Point
measures
and
variability
data
Total
Shulman et al.
(2013), US
1 0 1 0 0 0 1 0 1 1 5
Hass et al.
(2012), US
1 0 1 0 0 0 1 0 1 1 5
Allen et al.
(2010), AU
1 1 1 0 0 1 1 1 1 1 8
Schilling et al.
(2010), US
1 0 1 0 0 0 1 0 1 1 5
Dibble et al.
(2009), US
0 0 1 0 0 0 1 0 1 1 4
Dibble et al.
(2006), US
0 0 1 0 0 0 1 0 1 1 4
Hirsch et al.
(2003), US
1 0 1 0 0 0 1 0 1 1 5
Each criterion was scored as either 1 or 0 according to whether the criteria were met or not respectively; PEDro, physiotherapy evidence database.
FIGURE 2 | Forest plot showing the effects of progressive resistance training on gait speed in people with PD.
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FIGURE 3 | Forest plot showing the effects of progressive resistance training on leg strength in people with PD.
speed were examined by pooling post-intervention data from the
six studies (experimental n= 78; control n= 79; Figure 3). Over-
all, the pooled results suggest improvement in gait speed following
PRT was not statistically significant (total random effects= SMD
0.418, 95% CI −0.219 to 1.055). Only Schilling et al. (2010)
demonstrated a favorable effect for the use of PRT to improve
gait speed (SMD 1.535, 95% CI 0.440–2.631), while Shulman et al.
(2013) showed a favorable effect for the control group instead
(SMD−0.831, 95% CI−1.503 to−0.158).
BALANCE
Out of the seven studies reviewed, only three studies provided
either direct or indirect measures of the effects of PRT on bal-
ance in people with PD (Table 3). Overall, the MD across the
three studies suggest a non-statistically significant improvement
in balance measures following PRT. Although both studies by
Allen et al. (2010) and Schilling et al. (2010) did demonstrate
a trending improvement following PRT, no significant effects
were observed between experimental and control groups in either
studies. Only Hirsch et al. (2003) showed favorable support for
the use of PRT to improve balance, measured by the Equi-
Test Balance System, over 10 weeks of training (MD 13, 95%
CI, 8–18).
LEG STRENGTH
A total of six out of seven studies reviewed presented quantita-
tive measures of leg strength (Figure 3). The effects of PRT on leg
strength were examined by pooling post-intervention data from
the six trials (experimental n= 75; control n= 73). Overall, the
results significantly favored (p= 0.0014) the use of PRT to improve
leg strength in people with PD (total random effects= SMD 1.42,
95% CI 0.464–2.376). In particular, studies by Shulman et al.
(2013); Hass et al. (2012) and Hirsch et al. (2003) showed effect
sizes that were in favor of the experimental group compared to
the control group (Shulman: SMD 0.779, 95% CI 0.0816–1.476;
Table 3 | Effects of PRT on balance measures.
Trial Intervention
duration
(weeks)
Balance
measure
Mean difference
(MD) between
experimental vs
control groups
MD 95% CI
Allen et al.
(2010)
24 Static postural sway
(standing)
6.8 −36.1 to 49.7
Schilling
et al. (2010)
8 Activity-based
balance confidence
scale
6.7 −8.5 to 21.9
Hirsch et al.
(2003)
10 EquiTest balance
score
13 8–18
Hass: SMD 4.235, 95% CI 2.462–6.008; Hirsch: SMD 3.646, 95%
CI 1.853–5.439).
DISCUSSION
The aim of this meta-analysis was to determine if PRT was benefi-
cial to measures of gait, balance, and leg strength in people with PD
in comparison to other exercise interventions or no intervention.
Our main findings showed non-statistically significant improve-
ments in gait speed and balance measures that are concomitant
with a moderate but significant increase in leg strength following
an average of 16 weeks of PRT. Based on these findings, we were
not able to conclusively determine if PRT was indeed beneficial for
improving gait and balance in people with PD.
From our systematic review, we have determined that all studies
reported were of sound methodology (average PEDro score= 5)
which suggests that our findings were credible. However, only one
study (Allen et al., 2010) used intention-to-treat analysis, blinded
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assessors, and had concealed participant allocation while the rest
did not. In addition, both participants and therapists from all
seven studies were not blinded to the grouping in which par-
ticipants were allocated to. This presents as a major limitation
in the methodology of the current studies; however, it may also
be difficult, particularly in non-pharmacological interventions, to
blind both participants and therapists of the grouping in which
the participants will receive.
Results from our meta-analysis showed that PRT significantly
increased leg strength in people with mild-to-moderate severe
PD following PRT lasting from 8 to 24 weeks. The increase in
leg strength was expected and is consistent with the results from
a recent meta-analysis conducted by Lima et al. (2013). Despite
the large variation in training protocols used for PRT between
studies (duration: 8–24 weeks; frequency: 2–3sessions/week on
non-consecutive days), the intensity for each PRT intervention
was approximately 60–80% of one repetition maximum for each
exercise (Hirsch et al., 2003; Schilling et al., 2010; Hass et al., 2012)
or between 13 and 15 points on the rating-of-perceived exertion
scale (Dibble et al., 2006; Allen et al., 2010). Such training intensi-
ties are appropriate for strength adaptations even in healthy older
adults (>65 years) (Harris et al., 2004; Debeliso et al., 2005) and
are likely to support muscle morphology changes. Indeed, Dib-
ble et al. (2006) showed a significant increase in muscle volume
in people with mild-to-moderate PD that was correlated with
an increase in muscle strength following 12 weeks of high-force
eccentric training.
Apart from neuromuscular strength, gait speed and balance are
two other important lower limb functions that are often com-
promised in people with PD. Significant improvements in clinical
and functional measures of gait following aerobic exercise, par-
ticularly with treadmill walking, were demonstrated in a recent
meta-analysis by Shu et al. (2014). It is therefore reasonable to
suggest that lower limb PRT may confer similar benefits consider-
ing the ability for PRT to improve leg strength. Interestingly, our
results did not provide evidence for or against the effects of PRT
in improving overall gait speed measured by various walking tests,
such as the 6min and 10 m walk tests (Dibble et al., 2006; Shul-
man et al., 2013), short physical performance battery (Allen et al.,
2010), or by 3-dimensional motion analysis (Hass et al., 2012). It
is apparent that despite an increase in leg strength following PRT,
overall gait speed was not significantly improved. The results from
our meta-analysis were similar to those found in healthy aging par-
ticipants showing little effects of PRT on gait speed and balance
(Orr et al., 2008; Steib et al., 2010). Similarly, our findings could
not conclusively determine if indeed balance was improved by
PRT. Only three studies directly or indirectly measured indices of
balance. Allen et al. (2010) directly measured balance using static
posturography (sway distance on stable and unstable platforms)
and found no appreciable difference between the experimental
and control group. Similarly, Schilling et al. (2010) reported no
difference in the activity-based balanced scale between experimen-
tal and control groups. Only Hirsch et al. (2003) demonstrated a
significant effect of PRT on balance using the EquiTest Balance
System, which comprises a battery of computerized dynamic pos-
turography measures. The lack of balance measures reported in
PRT intervention studies limits our analysis and we suggest a cau-
tious approach is taken when evaluating this data as our findings
may not accurately reflect the efficacy of PRT on measures of
balance.
In light of our findings, several possible reasons could explain
why our meta-analysis did not show any significant improvements
in gait speed and balance. The first, and most likely, reason would
be that four out of seven studies reviewed used active controls
that performed low-intensity balance and treadmill-walking exer-
cises (Hirsch et al., 2003; Dibble et al., 2006, 2009; Shulman et al.,
2013). It should be noted that in the four studies that used an
active control group, significant improvements between pre and
post measures of balance and gait speed were also observed in
the PRT intervention groups. Secondly, gait speed is only one of
many measures of gait for which PRT may not specifically improve.
It may be argued that PRT could have resulted in significant
improvements in other gait measures such as gait variability, ini-
tiation velocity, stride length, and frequency. Indeed, results from
Hass et al. (2012) did show a significant improvement in initial
stride velocity following 10 weeks of PRT in mild-to-moderate PD
participants. Thirdly, it may also be argued that the PRT interven-
tion did not include task-specific exercises. In our review, three
studies use muscle-isolation (i.e., focusing on one muscle), open
kinetic chain exercises such as leg presses, hamstring curls, leg
extensions, and calf raises (Buckley et al., 2008; Schilling et al.,
2010; Shulman et al., 2013), while two studies used an eccentric
resistance training paradigm on a cycle ergometer (Dibble et al.,
2006, 2009) and only one study included functional, closed kinetic
chain exercises (i.e., squats, stepping up and down, and heel raises)
(Allen et al., 2010). It is possible that the non-specific nature of
the PRT exercises did not directly train gait-like movement pat-
terns, which limited the potential for gait improvements using
outcome measures identified. It may also be possible that the out-
come measures used in the studies were not sensitive enough to
detect changes in gait and balance that are associated with PRT.
Lastly, it could be that the small number of studies involved in this
meta-analysis and underpowered studies used were not enough
to detect a significant difference between groups (Turner et al.,
2013).
In conclusion, our meta-analysis examining the effect of PRT
on measures of gait and balance in people with PD found incon-
clusive evidence to support or refute the use of PRT. Based on our
findings and the understanding of the influence of task-specific
functional training and balance training for people with PD, it is
suggested that PRT should be used in conjunction with balance
and task-specific functional training to further improve mea-
sures of gait and balance. Finally, our systematic review revealed
a dearth of information regarding direct measures of balance
and gait, which should be included in future PRT intervention
studies.
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Concurrent transcranial direct current
stimulation and progressive resistance
training in Parkinson’s disease: study
protocol for a randomised controlled trial
Ashlee M. Hendy1, Alex Tillman1, Timo Rantalainen2, Makii Muthalib3, Liam Johnson4,5, Dawson J. Kidgell6,
Daniel Wundersitz1,7, Peter G. Enticott8 and Wei-Peng Teo1,2*
Abstract
Background: Parkinson’s disease (PD) results from a loss of dopamine in the brain, leading to movement
dysfunctions such as bradykinesia, postural instability, resting tremor and muscle rigidity. Furthermore, dopamine
deficiency in PD has been shown to result in maladaptive plasticity of the primary motor cortex (M1). Progressive
resistance training (PRT) is a popular intervention in PD that improves muscular strength and results in clinically
significant improvements on the Unified Parkinson’s Disease Rating Scale (UPDRS). In separate studies, the
application of anodal transcranial direct current stimulation (a-tDCS) to the M1 has been shown to improve motor
function in PD; however, the combined use of tDCS and PRT has not been investigated.
Methods/design: We propose a 6-week, double-blind randomised controlled trial combining M1 tDCS and PRT of the
lower body in participants (n= 42) with moderate PD (Hoehn and Yahr scale score 2–4). Supervised lower body PRT
combined with functional balance tasks will be performed three times per week with concurrent a-tDCS delivered at 2
mA for 20 minutes (a-tDCS group) or with sham tDCS (sham group). Control participants will receive standard care
(control group). Outcome measures will include functional strength, gait speed and variability, balance, neurophysiological
function at rest and during movement execution, and the UPDRS motor subscale, measured at baseline, 3 weeks (during),
6 weeks (post), and 9 weeks (retention). Ethical approval has been granted by the Deakin University Human Research
Ethics Committee (project number 2015-014), and the trial has been registered with the Australian New Zealand Clinical
Trials Registry (ACTRN12615001241527).
Discussion: This will be the first randomised controlled trial to combine PRT and a-tDCS targeting balance and gait in
people with PD. The study will elucidate the functional, clinical and neurophysiological outcomes of combined PRT and
a-tDCS. It is hypothesised that combined PRT and a-tDCS will significantly improve lower limb strength, postural sway,
gait speed and stride variability compared with PRT with sham tDCS. Further, we hypothesise that pre-frontal cortex
activation during dual-task cognitive and gait/balance activities will be reduced, and that M1 excitability and inhibition
will be augmented, following the combined PRT and a-tDCS intervention.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615001241527. Registered on 12
November 2015.
Keywords: Parkinson’s disease, Balance, Gait, Neuroplasticity, Non-invasive brain stimulation, fNIRS
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Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive movement disorder characterised by depletion of
dopamine in the substantia nigra, resulting in physical
symptoms such as bradykinesia, postural instability, rest-
ing tremor and muscle rigidity. PD is the second most
common neurodegenerative disorder [1], affecting 1 % of
people older than 60 years of age [2], which is of particular
concern as populations age. PD causes significant impair-
ments in gait and balance, which are often unresolved by
standard dopamine pharmacological treatment [3] and re-
sult in reduced quality of life and increased risk of falls [4].
There is growing evidence for the use of progressive
resistance training (PRT) to improve gait and lower limb
muscle strength in PD [5]. The inclusion of other func-
tional tasks, such as balance training, in PRT pro-
grammes has also been shown to decrease postural
sway, reduce the risk of falls, and improve quality of life
[6]. Importantly, functional PRT programmes have been
shown to induce neuroplastic changes in the primary
motor cortex (M1) of both healthy individuals [7] and
people with PD [8]. This is of particular interest, as mal-
adaptive M1 plasticity in patients with PD has been
linked to poorer outcomes in motor learning and move-
ment control [9, 10]. Evidence derived from transcranial
magnetic stimulation (TMS) studies has demonstrated
that patients with PD present with increased cortical
excitability and reduced inhibition at rest, which is evi-
denced by lower motor threshold, increased motor
evoked potential (MEP) amplitude, reduced short-
interval intra-cortical inhibition (SICI) [10] reduced si-
lent period [11]. Furthermore, reduced intra-cortical fa-
cilitation and absence of MEP size increase during
contraction suggests defective facilitatory cortical in-
puts, particularly for movement execution [12]. In
addition, the absence of a putative neuroplastic re-
sponse following paired associative stimulation [13, 14],
as compared with healthy control subjects, suggests
that the facilitation of M1 plasticity in patients with PD
may play an important role in the restoration and
maintenance of motor performance.
Transcranial direct current stimulation (tDCS) is a form
of non-invasive brain stimulation that has been shown to
modulate excitability of the M1 in a polarity-specific man-
ner when applied for short periods (10–20 minutes).
When anodal tDCS (a-tDCS) is applied to the M1,
there is a transient increase (up to 90 minutes) in ex-
citability and reduction SICI of underlying neurons
[15], as well as widespread changes in activation of
cortical and subcortical areas [16]. There is substan-
tial evidence to suggest that the application of a-tDCS
to the M1 results in improved motor function in
healthy populations, including increased performance
in skill and strength tasks [17, 18], and this may be
especially true when tDCS is applied during concur-
rent motor practice or training [19].
The use of tDCS as an independent intervention in PD
has produced promising results, with evidence for im-
proved working memory and executive function [20, 21],
reduced bradykinesia, and increased walking speed follow-
ing tDCS [22]. Importantly, clinically significant im-
provements in the motor component of the Unified
Parkinson’s Disease Rating Scale (UPDRS) have been
reported following bilateral a-tDCS of the M1 [23]. A
recent pilot study of eight participants reported for
the first time that combined gait training and M1 a-
tDCS showed promising improvements in walking
and balance measurements, but the researchers in
that study concluded that larger trials were required
to produce definitive results [24].
Given the existing evidence for enhancements in neu-
roplasticity and motor performance following both PRT
and tDCS as independent treatments, it is reasonable to
conclude that the combination of these two interven-
tions may further augment functional benefits in pa-
tients with PD. Indeed, a combination of a-tDCS and
motor training appears to produce a compounding effect
on motor performance and neurophysiological adapta-
tions in healthy populations [25, 26] and stroke-affected
individuals [27, 28]; however, the application of a-tDCS
during PRT and balance training in PD is yet to be
investigated.
Methods/design
Aims
The primary aim of this pilot study is to determine the
effects of a 6-week lower limb balance and PRT inter-
vention with concurrent a-tDCS on gait, balance,
strength and UPDRS motor scores in patients with PD.
In addition, we will investigate neurophysiological adap-
tations in M1 excitability and pre-frontal cortex (PFC)
activation as potential underlying mechanisms. It is
hypothesised that the combination of PRT and a-tDCS
will produce favourable functional motor outcomes and
neuroplasticity beyond the effects of PRT alone.
Eligibility and recruitment
The recruitment, screening and randomisation process
is shown in Fig. 1. Potential participants will be recruited
on a voluntary basis with the assistance of the Australian
Parkinson’s Disease Registry and neurology clinics within
the Melbourne metropolitan area. All participants will
provide written informed consent as well as written ap-
proval from their general practitioner before partaking
in physical exercise. Prior to enrolment in the study, a
series of screening questionnaires will be completed by
telephone to determine eligibility.
The following inclusion criteria will be applied:
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1. Diagnosed with PD by an independent neurologist
2. Moderate motor symptoms (score between 2 and 4
on the Hoehn and Yahr scale, as assessed by an
independent neurologist and confirmed at initial
assessment by a blinded researcher)
3. Stable drug regime for the full duration of the study
and the 6 weeks preceding the study
4. Self-reported history of one or more falls in the last
24 months
5. Not currently undertaking a regular exercise
programme
Potential participants will be excluded if they present
with any of the following:
1. Severe motor impairments or injuries that will
impair the ability to perform lower limb PRT
(confirmed at initial assessment by blinded
researcher)
2. Previously diagnosed neurological condition separate
from PD (stroke, dementia, epilepsy)
3. Metal implants in the head (i.e., deep brain
stimulator or aneurysm clips), which are
contraindicated with non-invasive brain stimulation
techniques
Randomisation and blinding
Once recruited, simple randomisation using a compu-
terised sequence generator will be used to allocate par-
ticipants to one of three study groups (a-tDCS, sham or
control). Opaque envelopes will be used to conceal the
group allocation, which will not be revealed until after
all data have been analysed. A researcher who is
otherwise removed from the study will program the
tDCS machine before PRT sessions to ensure double-
blinding of both researcher and participant. Participants
allocated to the control group will be notified of their al-
location and will be asked to attend assessment sessions
only.
Study overview
The study will run for a period of 9 weeks in total, in-
cluding a 6-week intervention period and a 3-week
follow-up. Participants will be randomly allocated to one
of three groups:
1. a-tDCS (required to perform PRT and balance
training while receiving a-tDCS)
2. Sham (required to perform PRT and balance training
while receiving sham tDCS)
3. Control (to receive standard care)
Exercise sessions will include PRT and balance training
for a duration of approximately 40 minutes, and they
will be completed on 3 non-consecutive days per week
(18 sessions in total). Assessment sessions to evaluate
outcome measures will take place at four time points:
baseline (T0), mid-intervention at 3 weeks (T3), post-
intervention at 6 weeks (T6) and retention at 9 weeks
(T9). Assessment sessions will take approximately 3 h
and will occur at the same time of day for each time
point. All sessions will take place at the Deakin Univer-
sity Burwood campus in a specialised clinical exercise
gym and laboratory facility. The control group will re-
ceive standard care for the duration of the study and will
be required only to attend the assessment sessions. Fig-
ure 2 provides an overview of the study time frame and
sessions. For the duration of the study, all participants
will continue with their usual care and medications as
prescribed by their physician. Any changes in medication
status during the trial will be documented, and partici-
pants will be allowed to continue with the programme.
Intervention
Strength and balance training
Participants will be required to attend PRT and balance
training sessions at Deakin University Burwood campus
three times per week, on non-consecutive days, for 6
weeks. All PRT exercises will be aimed at the lower body
and will include the following: leg press performed on
fixed pneumatic gym equipment (Air300; Keiser, Fresno,
CA, USA) (see Fig. 3); sit to stand, progressing to body
weight squat and addition of weight vest (5, 10 or 15 kg)
(see Fig. 4); standing bilateral calf raise, progressing to
unilateral calf raise and weighted vest (se Fig. 5); and
seated unilateral dorsiflexion with free weight dumb-bell
(see Fig. 6).
Fig. 1 Flow diagram of recruitment, screening and randomisation
process. a-tDCS anodal transcranial direct current stimulation
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Fig. 2 Study timeline (a) and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT 2013) diagram (b) illustrate the schedule of
enrolment, interventions and assessments. fNIRS functional near-infrared spectroscopy, FTSTS Five Times Sit-to-Stand Test, PRT progressive resistance
training, tDCS transcranial direct current stimulation, TMS transcranial magnetic stimulation, TUG Timed Up and Go Test, UPDRS Unified Parkinson’s
Disease Rating Scale
Fig. 3 Example of seated leg press
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Participants will perform three sets of six to eight rep-
etitions of each exercise, with resistance set at 70 % of
their recorded single-repetition maximum (1RM). Repe-
tition timing will be externally paced by an audible
metronome consisting of 3-second concentric and 3-
second eccentric contractions. For each exercise, resist-
ance will be increased by 5 % when all sets can be com-
pleted with correct repetition timing and technique, as
assessed by a trained exercise physiologist.
Between each set of exercises, participants will per-
form a functional balance task:
1. Tandem stance, 4 × 15 seconds alternating the
leading foot
2. Single-leg stance, 4 × 15 seconds alternating the
leading foot
3. Tandem walk, 3 × 12 steps, heel to toe, in a straight line
4. Hurdle walk, six laps of four hurdles (height = 30 cm)
Fig. 4 Example of body weight squat
Fig. 5 Example of standing bilateral calf raise
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Stance tasks will be performed with the assistance
of the trainer if required and will be progressed by
using unstable foam surfaces, duraDiscs (AOK Health,
Newcastle, Australia), performing with the eyes
closed, and receiving multi-directional perturbations.
Walking tasks will be progressed by performing a
concurrent dual task (naming colours, cities, coun-
tries, and so forth), adding 1-kg ankle weights, and
being instructed to ‘pause’ and ‘reverse’ mid-task. Par-
ticipants will advance to the next progression when
the exercise physiologist deems that they can compe-
tently complete the task.
Transcranial direct current stimulation
A tDCS Stimulator Model 101 (TCT Research Limited,
Hong Kong, China) will be used to deliver a-tDCS and
sham tDCS. For a-tDCS, a current of 2 mA will be deliv-
ered through two 50-cm2 electrodes, producing a
current density of 0.04 mA/cm2. The anode will be
soaked in saline and placed centrally over the left and
right motor representation of the lower limb, as pre-
determined with TMS, and secured with adjustable rub-
ber straps. The cathode will be placed on the right tra-
pezius muscle at the base of the neck, with Ten20
conductive gel (Weaver and Company, Aurora, CO,
USA) used to secure the rubber electrode directly onto
the skin. Figure 7 demonstrates the electrode montage.
Stimulation will commence at the beginning of the train-
ing session and will be delivered for a duration of 20
minutes (typically ceasing approximately halfway
through the session). Bioelectrical impedance will be
monitored throughout the stimulation protocol and will
not exceed 55 kΩ. Sham tDCS will involve an identical
electrode montage, with stimulation ceasing after a 20-
second ramp-up period to provide equivalent scalp sen-
sation. A pseudo-stimulation feature built into the direct
current stimulator allows for the device to be pre-
programed to deliver sham stimulation while maintain-
ing identical appearance, operation and screen prompts.
This was conducted prior to each session by a laboratory
assistant, enabling double-blinding of both researcher
and participant.
Compliance requirements
Participants will be required to complete a minimum of
16 of the 18 scheduled training sessions (representing >85
% attendance). Testing of outcome measures (T0, T3, T6
and T9) will be completed within 72 h of the scheduled
time point, determined from the commencement of the
training programme.
Outcome measures
Functional strength of the lower limb
Participants will perform 1RM tests to assess maximal
voluntary strength of the lower limb muscles. A standard
leg press and leg extension exercise will be performed
on fixed pneumatic gym equipment (Air300; Keiser).
Plantarflexion will be measured bilaterally on the seated
Fig. 6 Example of unilateral dorsiflexion with free-weight dumb-bell
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leg press by placing the toes on the footplate and using
the ankle dorsiflexion to press the plate forward while
maintaining 180-degree knee extension. The unweighted
movement distance is marked on the equipment, allow-
ing the researcher to ensure that full range of movement
is maintained during maximal attempts. Dorsiflexion will
be measured unilaterally while the participant is seated
with the heel positioned on a 25-cm step. A custom-
made static strap weighted with an adjustable dumb-bell
will be placed over the metatarsophalangeal joint, and
the participant will be required to lift the dumb-bell
smoothly through 45 degrees of dorsiflexion, measured
by the researcher with a goniometer. All exercises have
been chosen carefully to minimise any risk of falling or
injury whilst being performed.
An initial starting resistance of approximately 20 %
1RM will be estimated by the researcher to familiarise
the participant with the movement, and five to ten repe-
titions will be performed to provide a warm-up. The re-
searcher will then select an appropriate resistance for a
near-maximal effort, and the participant will be required
to perform a single repetition of the exercise while main-
taining correct technique. The resistance will be in-
creased in 5–10 % increments as appropriate, until the
participant can no longer perform a full repetition. Two
minutes of rest will separate each attempt, and verbal
encouragement will be provided. The highest resistance
used to perform a successful repetition will be recorded
as the 1RM in kilograms.
Functional assessments
Motor function specific to PD will be assessed with sec-
tion III of the UPDRS-III. The same independent assessor
will perform the test at all time points and will be blinded
to the intervention group. The assessment will be per-
formed at the same time of day and will precede all other
tests to ensure fatigue does not confound performance.
A Timed Up-and-Go Test (TUG) will also be per-
formed to assess motor function and speed [29]. Partici-
pants will be asked to rise from a 46-cm chair, walk
around a plastic cone located 3 m away and return to
the chair as quickly as possible. The arms of the chair
may be used if necessary. The test ends when the par-
ticipant assumes the original seated position, and time is
recorded. Regular enclosed footwear will be worn, and
customary walking aids may be used if required. The
average time in seconds from three trials will serve as
the TUG score.
The Berg Balance Scale will be used to assess func-
tional balance [30]. The assessment will take ap-
proximately 20 minutes and will consist of 14 static
and dynamic balance tasks which are scored from 0
to 4 by a trained exercise physiologist. The same as-
sessor will perform the test at all time points and
will be blinded to the intervention group. High valid-
ity and reliability of the Berg Balance Scale in neuro-
logical patient populations have previously been
established [31].
The Five Times Sit-to-Stand Test (FTSTS) will be used
to assess mobility and lower limb acceleration [32]. Par-
ticipants will be seated in a 46-cm chair without arm-
rests and will be asked to begin with their arms folded
across the chest and their back upright against the back-
rest. Participants will perform five repetitions of moving
from the seated position to standing, with the legs fully
extended and hip and knee joints, as quickly as possible.
The total time taken to complete five repetitions will be
recorded in seconds. An inertial measurement unit
(Nanotrak; Catapult Innovations, Docklands, Australia)
worn on the right hip, sampling accelerations and gy-
rations at 100 Hz, will be used to determine vertical
acceleration [33]. Previous researchers have reported
high validity and reliability of the FTSTS in patients
with PD [34].
Fig. 7 Example of electrode montage for anodal transcranial direct current stimulation
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Gait
Gait will be assessed using the ProtoKinetics Zeno 4.9-
metre walkway (ZenoMetrics LLC, Peekskill, NY, USA).
The walkway has a 2-foot-wide grid of pressure-sensing
pads with a spatial resolution of 0.5 cm and a sampling
frequency of 120 Hz. Participants will be asked to per-
form the walking trials at their preferred walking speed
while wearing comfortable footwear. Two different gait
conditions will be assessed: (1) normal walking and (2)
walking while counting backward in 7s from a random
three-digit number, termed dual-task gait. Three trials
of each condition will be performed in random order. A
trial begins by sitting silently on a chair for 30 seconds,
then standing up and walking to a starting line located 1
m from the walkway. From the start line, the participant
is asked to walk up and back four times to another line
1 m beyond the end of the walkway before returning to
the seated position. The 30-second rest periods between
each trial allow for accurate functional near-infrared
spectroscopy (fNIRS) hemodynamic brain imaging (see
‘Functional near-infrared spectroscopy’ section below for
details). The mean asymmetry and variability will be cal-
culated using all of the steps of all of the trials for a
given condition: step velocity (in meters/second), step
duration (in seconds) step length (in centimetres),
double support time (in seconds) and stride width (in
centimetres). Step variability will be calculated on the
basis of residuals, as suggested in previous literature
[35]. Gait assessments using instrumented walkways
have been shown to be repeatable in older adults [35,
36].
While undertaking the gait assessments, the partici-
pants will be asked to wear an inertial measurement unit
on an elastic belt (Nanotrak) for sampling of accelera-
tions and gyrations at 100 Hz at lumbar vertebrae L3–
L5, in line with the spinous processes. Harmonic ratio
[37] and multi-scale sample entropy will be calculated
from the recorded vertical and resultant signals [38].
These inertial measurement unit-based variables have
previously been shown to be repeatable [38].
Posturography
Static balance will be assessed with a 45-second bipedal
standing test in three separate conditions: (1) eyes open,
(2) eyes closed and (3) dual-task balance (eyes open
while counting backwards in serial 7s from a random
three-digit number). All tests will be conducted at pre-
ferred stance width, which will be recorded at baseline
and maintained during all subsequent tests. A black dot
(10-cm diameter) printed on white paper will be affixed
3 m in front of the participants at eye height, and the
participants will be asked to fix their gaze on the dot
while undertaking the eyes-open tests. Again, 30-second
rest periods between each trial will be provided for
concurrent fNIRS sampling. The measurement will be
conducted on a portable force plate (AccuGait; AMTI,
Watertown, MA, USA) sampling ground reaction forces
at 500 Hz. Instantaneous centre of pressure will be
calculated on the basis of recorded signals, and centre-
of-pressure travel velocity (millimetres/second) will be
calculated to represent static balance. The repeatability
of centre-of-pressure travel analyses has been demon-
strated in previous studies [39].
Transcranial magnetic stimulation and electromyography
Corticospinal excitability and intra-cortical inhibition of
the tibialis anterior (TA) muscle will be assessed using
two Magstim 2002 stimulators (Magstim, Whitland, UK)
connected to a 110-mm, concave, double-cone coil
(maximum output 1.4 T). The coil will be positioned
with anterior-to-posterior current flow, and sites near
the estimated right TA motor representation (approxi-
mately 1–3 cm lateral and anterior to the vertex) will be
explored to determine the optimal site, which will be
marked on the scalp with a permanent marker. Resting
motor threshold (RMT) and active motor threshold
(AMT) will be defined as the lowest stimulator output
required to achieve an MEP with an amplitude greater
than 0.05 mV and 0.20 mV in six of ten stimuli, respect-
ively. Corticospinal excitability will be determined by de-
livering ten single-pulse stimuli at suprathreshold
intensities of 1.3 × RMT and 1.5 × RMT. In accordance
with previous literature [40], SICI will be determined by
delivering ten paired-pulse stimuli, with the conditioning
stimulus set at 0.8 × RMT, the test stimulus set at 1.3 ×
RMT, and an interstimulus interval of 3 milliseconds.
Intra-cortical inhibition will be determined by calculat-
ing the SICI ratio (average paired-pulse MEP amplitude/
average single-pulse MEP amplitude); thus, SICI ratio
values closer to 1 will represent lower levels of intra-
cortical inhibition, while SICI ratio values closer to 0 will
represent higher levels of intra-cortical inhibition. The
total of 30 stimuli (20 single pulses and 10 paired pulses)
will be delivered in sets of 5 in a randomised order.
Once the TMS protocol has been completed with the TA
muscle at rest, the same protocol will be repeated in an ac-
tive muscle state while the participant maintains a low-level
background contraction (10 % of maximum force). The
participant’s maximal voluntary isometric contraction
(MVIC) of the right TA will first be determined using a
force transducer (LMD500; Futek, Irvine, CA, USA)
mounted in a custom-made timber frame. The participant
will be seated with the knee and ankle positioned at 90 de-
grees and the transducer positioned above the distal end
of the metatarsals. The participant will be instructed to
dorsiflex at the ankle with the base of the heel remaining
on the floor, producing an isometric contraction against
the force transducer. The peak force obtained from three
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maximal efforts with 2 minutes rest between attempts
with the highest force output will be recorded as the par-
ticipant’s MVIC. Verbal encouragement will be provided,
and visual feedback of force will be visible on a monitor
directly in front of the participant at eye level. To
complete the TMS protocol in the active muscle condi-
tion, 10 % of the MVIC will be calculated and indicated by
a line on the monitor. The participant will be asked to
maintain the force feedback level with the line while TMS
is delivered, with short rest periods (5–10 seconds) be-
tween each set of five stimuli. AMT will be defined as the
lowest stimulator output required to achieve an MEP with
an amplitude greater than 0.2 mV in six of ten stimuli.
Maximal compound waves (M-waves) will be collected
during each session and used to normalise MEP re-
sponses. This method prevents any changes in peripheral
muscle excitability acting as a confounder when deter-
mining corticospinal excitability [41]. A DS7A constant
current electrical stimulator (Digitimer, Welwyn Garden
City, UK) will be used to deliver supramaximal stimula-
tion to the common peroneal nerve. The head of the
fibula will be palpated, and a stimulating bar will be po-
sitioned directly inferior, with light pressure applied.
Stimulation will be delivered at increasing current
strengths until the muscle response reaches a plateau,
then increased 10–20 % to ensure maximal stimulation
is achieved. The largest resulting peak-to-peak muscle
response will be reported as maximal M-wave amplitude.
The M-wave will be obtained in both resting and active
(10 % MVIC) muscle conditions and will be used to nor-
malise resting and active MEPs, respectively.
All muscle responses (MEPs and M-waves) will be re-
corded using surface electromyography (sEMG). The
area of electrode placement will be shaved to remove
hair, rubbed with abrasive gel to remove dead skin, and
then cleaned with 70 % isopropyl alcohol. Bipolar gel
Ag-AgCl electrodes (8-mm diameter, model E258S; BIO-
PAC Systems, Goleta, CA, USA) will be placed over the
TA muscle belly with an inter-electrode distance of 2
cm. A grounding electrode will be placed over the pa-
tella and used as a common reference. The electrode
sites will be marked with a permanent marker, measured
in reference to the tibial tuberosity, and photographed to
ensure consistent electrode placement between sessions.
All cables will be fastened with tape to prevent move-
ment artifact. All sEMG signals (including MEPs) will be
amplified (×1000) with band-pass filtering between 13
Hz and 1000 Hz, digitised online at 2 KHz for 500 milli-
seconds, and recorded and analysed using PowerLab 4/
35 (ADInstruments, Bella Vista, Australia).
Functional near-infrared spectroscopy
Mechanisms underlying difficulties in dual-task gait and
balance are largely unclear. However, the PFC, which is
primarily involved in attention and executive function, is
also involved in human balance and locomotion [42],
which likely plays an important role. Although attention
and executive function that depend on the PFC are often
affected in PD [43–45], patients may rely more on the
PFC because of reduced movement automaticity of dys-
functional basal ganglia circuits [46–48]. Consequently,
altered functioning of the PFC during dual-task gait and
balance in PD might explain the difficulties of patients
with PD and therefore will be examined in this study
using fNIRS.
fNIRS neuroimaging uses optical technology to meas-
ure the relative concentrations of oxygenated haemoglo-
bin (O2Hb) and deoxygenated haemoglobin (HHb) in
the cortical layer microcirculation [49], producing cor-
tical activation data consistent with data obtained from
functional magnetic resonance imaging [50, 51]. Portable
fNIRS has successfully been used to measure PFC activa-
tion during dual-task walking in patients with PD [52]
and in other populations [53–55]. A PortaLite™ fNIRS
system (Artinis Medical Systems, Elst, The Netherlands)
will be used to assess PFC activation during several
tasks, including counting backwards in 7s from a ran-
dom three-digit number while seated and during the
simple and dual-task gait-and-balance assessments de-
scribed in the previous section.
The PortaLite™ device has three transmitters and one
receiver, with transmitter-receiver distances of 30, 35
and 40 mm. Near-infrared light is transmitted with two
wavelengths, 760 nm and 850 nm, and data will be sam-
pled with a frequency of 10 Hz. The PortaLite™ device
uses wireless technology (Bluetooth, Kirkland, WA,
USA), allowing participants to perform the tasks without
restriction of wires. Since a previous preliminary study
showed no significant differences between left- or
right-side PFC activation during dual-task walking in
PD [52] the PortaLite™ device will be placed on the
left forehead F3 site using the international 10–20
electroencephalography system. This location will tar-
get the left Brodmann’s areas 9 and 10, which corres-
pond to the dorsolateral and anterior PFC [56, 57].
The device will be shielded from ambient light by
covering the forehead with a black piece of fabric.
Oxysoft software (Artinis Medical Systems) will be
used for data collection and analysis.
On the basis of different absorption spectra, concen-
tration changes of O2Hb and HHb in the targeted PFC
area will be calculated from the changes in detected
light intensity. This is done using the modified Beer-
Lambert law, assuming constant scattering [58]. The
differential path length factor, which accounts for the
increased distance travelled by light due to scattering,
will be set to 6 for all participants. For analysis, O2Hb
and HHb signals of the three channels (the three
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transmitter-receiver distances) will be averaged. The
moving SD-based movement artifact reduction algo-
rithm method will be used within each trial to remove
movement artifacts and other noise from the fNIRS sig-
nals [59]. The threshold for artifact detection will be set
to 0.45 for O2Hb and 0.18 for HHb [52], with a window
length for moving SD calculation at 0.5 seconds and a
window length for artifact correction (locally weighted
scatterplot smoothing window) on 1 second. The fNIRS
signals will then be linearly de-trended per trial and low-
pass-filtered at 0.1 Hz to remove heart rate from the sig-
nals. To enable direct comparison of the different trials
within each task, the filtered signals will be biased, using
the average concentration of the 5 seconds before the
‘start’ instruction as a reference (zero). Then, individual
trials will be averaged per task to create three mean time
course signals per person, which will then be averaged
over all participants. Finally, the peak and mean concen-
trations (O2Hb and HHb) during the task and rest periods
will be calculated over all trials for all participants and
then averaged for each of the tasks.
Adverse events
All adverse events will be self-reported by the partici-
pants at 3, 6 and 9 weeks and assessed by the research
staff for seriousness, expectedness and causality follow-
ing the guidelines recommended by the National Health
and Medical Research Council (NHMRC) position state-
ment for monitoring and reporting of safety for clinical
trials ( https://www.nhmrc.gov.au/guidelines-publica-
tions/e112). In this study, an adverse event will be de-
fined as any health-related unfavourable or unintended
medical occurrence (sign, symptom, syndrome, illness)
that develops or worsens during the period of the trial.
Adverse events will be closely monitored until resolution
or stabilisation is achieved or until it has been shown
that the study intervention is not the cause of the injury.
Participants will be asked to contact the research staff
immediately in the event of a serious adverse event. Any
adverse event sustained during the exercise programme
will be recorded by the trainers and immediately re-
ported to the research staff. The chief investigator will
be informed of the adverse event and shall determine its
seriousness and causality in conjunction with any med-
ical staff treating the event. A serious adverse event that
is deemed related to, or suspected to be related to, the
exercise intervention will be reported to the ethics
committee.
Data management and archiving
All data will be de-identified, coded and stored on a
Deakin University server that can be accessed only
from password-protected computers. Any physical
copies of the data recording sheet will be stored in
locked filing cabinets at Deakin University (Burwood).
All data will be checked monthly by the chief investi-
gator to ensure that all protocols and ethical gu-
idelines for data collection and analysis are followed.
All study-related documents will be archived at Dea-
kin University at the end of the study for a minimum
of 6 years, which is in line with current ethical
requirements.
Dissemination plan
Findings derived from the primary outcome analysis of
this trial will be reported in journal articles, which will
include results regardless of the direction or magnitude
of the effect. The results will also be presented at leading
national and international conferences and clinical for-
ums and to other relevant health professionals and
stakeholders, as well as to the participants. All investiga-
tors will have the opportunity to be listed as an author
of future publications, in accordance with the Australian
Government National Health and Medical Research
Council guidelines [60].
Sample size calculation and statistical analysis
Gait speed, static balance and UPDRS-III at T6 will
serve as primary outcome measures, with all other as-
sessments and time points serving as secondary outcome
measures. Based on the effect size observed in a recent
study using a-tDCS during walking exercise [24], it is es-
timated that 42 participants randomised equally to three
groups will be needed. Fourteen participants in each
intervention group (a-tDCS, sham, control) will provide
at least 80 % power to detect a 10–15 % difference in
gait speed and static balance (centre of pressure), assum-
ing a 5 % significance level. In functional assessments, a
10–15 % difference equates to an increase of 5.2 points
on the UPDRS-III, which indicates a moderate clinically
important difference [61].
A two-way, repeated-measures, mixed-design analysis of
variance with factors time (T0 vs. T3 vs. T6 vs. T9) and
treatment (a-tDCS vs. sham vs. control) will be used to de-
termine any effect of the intervention on balance, gait
speed and measures of brain physiology. False discovery
rate analysis will be applied to determine when and where
significance is found. An alpha level of P < 0.05 will be set
to determine significance.
Where possible, we will obtain endpoint measures
from all withdrawals and will include all randomised
subjects in the final analysis. For participants who are
lost to follow-up, missing data will be handled with mul-
tiple imputation. As this approach makes an untestable
assumption that data are missing at random (i.e., missing
data can be predicted from the observed data) [62], we
will perform sensitivity analysis to evaluate the effect of
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potential non-random attrition [63]. Sensitivity analyses
will employ simulation and will test a range of scenarios
assuming plausible arm-specific differences in outcomes
for individuals who were lost to follow-up [64].
Discussion
To our knowledge, this pilot study will be the first ran-
domised controlled trial to combine functional PRT and
a-tDCS of the M1 to target balance and gait in people
with PD. The study has been designed to elucidate the
functional, clinical and neurophysiological outcomes of
combined PRT and a-tDCS. It is hypothesised that the
combination of PRT and a-tDCS will benefit lower limb
strength, postural sway, gait speed and stride variability
by a greater magnitude than PRT with sham-tDCS.
Further, we hypothesise that PFC activation during dual-
task cognitive and gait-and-balance activities will be
reduced, and that M1 corticospinal excitability and in-
hibition will be augmented, following the combined PRT
and a-tDCS intervention.
The study is strengthened by a double-blind approach to
tDCS stimulation type (a-tDCS or sham), with participants,
outcome assessors and exercise supervisors remaining un-
aware of stimulation type for the duration of the study. Be-
cause of the nature of the exercise interventions,
participants in the control group cannot be blinded; how-
ever, outcome assessors will remain unaware of allocation.
The PRT programme used in this study has been devel-
oped specifically to target lower limb strength and incorp-
orate functional balance tasks that will maximise gains in
mobility and reduce postural sway. All PRT sessions will
be conducted one-to-one with an experienced exercise
physiologist to ensure each participant will be trained con-
sistently. Progressions will be administered according to
individual performance and will be recorded in detail to
enable a post-intervention comparison, which will allow
us to detect any potential inequality of exercise load be-
tween groups. Outcome measures have been carefully se-
lected to enable us to detect functionally and clinically
relevant effects of the intervention (UPDRS, TUG, FTSTS,
Berg Balance Scale and 1RM lower limb strength tests), as
well as to provide sensitive biomechanical analysis with
previously validated techniques (step velocity, duration,
length, double-support time, stride width and centre-of-
pressure travel velocity). Neurophysiological assessments
will provide insight into adaptive plasticity that may
underpin any changes in functional capability, with TMS
used to detect changes in corticospinal excitability and in-
hibition of the M1 lower limb representation and fNIRS
neuroimaging of the PFC used during combined cognitive
and motor tasks to quantify changes in PFC activation.
A limitation of this study is the reduced sample size,
which has been selected for the feasibility of conducting
a one-to-one, 6-week exercise intervention. Despite this,
sample size calculations indicate that any clinically sig-
nificant benefits of combining a-tDCS with PRT will be
detected statistically. If successful, pilot data from this
study are vital to informing larger-scale clinical trials in
patients with PD, and the additional investigation of
underpinning neurophysiological mechanisms may also
be translated to inform future treatment options for a
range of other movement disorders.
The safe and inexpensive nature of a-tDCS is well
suited for translation to existing and established PD re-
habilitation programmes and services. While current
pharmacological treatments in PD provide significant
benefits to reduce the impact of some motor symptoms,
bradykinesia and impaired postural stability often con-
tinue to impact patients significantly [3]. These symp-
toms have a detrimental effect of the quality of life of
patients with PD and contribute to an increased risk of
falls [4]. Rates of falls among patients with PD are twice
as high as those in the general older population, with 46
% of people with PD experiencing recurrent falls each
year [65, 66]. Falls often result in hospitalisation [67] as
well as longer-term injuries such as fractures that further
restrict physical capability and contribute to a cycle of
secondary health complications and a loss of independ-
ence [68]. Effective interventions targeting balance and
gait will reduce the burden of PD on the individual,
family and carers, as well as the healthcare system. We
anticipate that the findings of this study will inform
large-scale randomised controlled trials aimed at imple-
menting PRT and a-tDCS in community- and home-
based settings to treat the motor symptoms of PD.
Trial status
Seventeen participants have completed the protocol in
full, and six are currently undergoing PRT. One partici-
pant has failed to complete the intervention due to ill-
ness. Recruitment of participants is ongoing.
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APPENDIX C 
Participant 
ID no. 
Age Gender 
Disease 
duration 
Disease 
severity 
(H&Y 
score) 
Medication 
type 
(Brand) 
Medication dose 
PD005 70 M 6 years 2 Stalevo 
Madopar 
HBS 
1 x 200/50/200mg 4 
x daily 
100/25mg 1 x daily 
2 caps 1 x daily 
PD014 77 M 8 years 3 Madopar 
HBS 
Azilect 
1 x 200/50mg 4 x 
daily 
2 caps 1 x daily 
1 x 5mg 1 x daily 
PD018 54 M 3 years 2.5 Kinson 
Comtan 
Sifrol 
Azilect 
2 x 100/25mg 3 x 
daily 
1 x 200mg 3 x daily 
1 x 0.75mg 1 x daily 
1 x 1mg 1 x daily 
PD019 72 M 4 years 2 Madopar 
Azilect 
1 x 100/25mg 3 x 
daily 
1 x 1mg 3 x daily 
PD020 63 M 3 years 2.5 Madapor 
Sifrol 
Azilect 
1 x 200/50mg 5 x 
daily 
1 x 1.5mg 1 x daily 
1 x 5mg 1 x daily 
PD021 73 M 16 years 2.5 Madapar 
Symmtrel 
1 x 150/100/25mg 4 
x daily 
1 x daily 
PD022 75 F 4 years 2.5 Madapar 
Neuropro 
Azalect 
Symmetrel 
1 x 62.5mg 3 x daily 
6mg 1 x daily 
1 x 1mg 1 x daily 
100mg 1 x daily 
PD 023 78 F 1.5 years 2.5 Medopar 100/25mg 1 x daily 
PD024 68 F 2 years 3 Kinson  125/50mg 1 x daily 
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Participant 
ID no. 
Age Gender 
Disease 
duration 
Disease 
severity 
(H&Y 
score) 
Medication 
type 
(Brand) 
Medication dose 
PD025 73 F 6 years 3 Medopar 
Stalevo 
Celapram 
Azilect 
Neuro- 
rotigotine 
1 x 25mg 1 x daily 
1 x 100/25/200mg 4 
x daily 
1 x 10mg 1 x daily 
1 x 1mg x daily 
1 x 6mg 1 x daily 
PD 026 71 M 8 years 2.5 Medopar 100/25mg 4 x daily 
PD 027 61 M 3 years 2 Sinemat 100/25mg 4 x daily 
PD 028 71 M 8 years 2.5 Kinson 100/25mg 4 x daily 
PD 029 74 M 5 years 3 Stalevo 150/37.5/200/200mg 
4 x daily 
PD 030 78 M 7 years 2.5 Kinson 25/100mg 4 x daily 
PD 031 74 M 5.5 years 3 Stalevo 150/37.5/200/200mg 
4 x daily 
PD 032 67 F 3 years 2 Medopar 
Sifrol 
1.5 x 125mg 3 x 
daily 
0.25mg 1 x daily 
PD 033 63 M 2.5 years 2 Kinson 100/25mg 3 x daily 
PD 034 69 M 3 years 3 Medopar 
Sifrol 
Azilect 
250mg 3 x daily 
1.5mg 1 x daily 
1mg 1 x daily 
PD 035 78 M 4 years 2.5 Kinson 
Neuropatch 
2 x 100/25mg 3 x 
daily 
1 patch 2mg &  
1 patch 4mg 
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Participant 
ID no. 
Age Gender 
Disease 
duration 
Disease 
severity 
(H&Y 
score) 
Medication 
type 
(Brand) 
Medication dose 
PD 036 66 M 6 years 2.5 Sinemat 
Sifrol 
Azilect 
250/25mg 3 x daily 
0.125mg 1 x nightly 
1mg 1 x nightly 
PD 038 72 F 7 years 2 Medopar 
Sifrol 
100/25mg 3 x daily 
0.125mg 1 x daily 
PD 039 69 F 3 years 2.5 Sinemat 
Sifrol 
300mg 3 x daily 
75mg 1 x daily 
PD 040 74 M 4 years 2.5 Medopar 
Azilect 
Symmetrel 
200/50mg 3 x daily 
1mg 1 x daily 
100mg 2 x daily 
PD 041 72 M 8 years 2 Medopar 100/25mg 4 x daily 
PD 042 70 F 5 years 2.5 Medopar 100/25mg 2 x daily 
PD 043 81 M 10 years 3 Medopar 
Azilect 
Sifrol 
100/25 2 x daily 
1mg 1 x daily 
1.5mg 1 x daily 
PD 044 63 M 3 years 2 Kinson 100mg 3 x daily 
PD 045 66 M 3 years 2.5 Medopar 
Sifrol 
200/50mg 3 x daily 
0.75mg 1 x daily 
1.5mg 1 x daily 
PD 046 75 M 7 years 2.5 Kinson 
Sifrol 
100/25mg 3 x daily 
1.50mg 1 x daily 
PD 047 75 M 4 years 2 Kinson 
Azilect 
100/25mg 3 x daily 
1mg 1 x daily 
PD 048 77 F 4 years 2 Kinson 100/25mg 3 x daily 
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APPENDIX D 
Transcranial Magnetic Stimulation† (TMS) Adult Safety Screen 
Name: 
Date:
Age:
Please answer the following: 
Have you ever:  
Had an adverse reaction to TMS?  Yes     No 
Had a seizure?  Yes     No 
Had an electroencephalogram (EEG)?  Yes     No 
Had a stroke?  Yes     No 
Had a serious head injury (include neurosurgery)? Yes     No 
Had any other brain-related condition?  Yes     No 
Had any illness that caused brain injury? Yes     No 
Do you have any metal in your head (outside the mouth)  
such as shrapnel, surgical clips, or fragments from welding 
or metalwork?  Yes     No 
Do you have any implanted devices such  
as cardiac pacemakers, medical pumps, or intracardiac lines? Yes     No 
Do you suffer from frequent or severe headaches?  Yes     No 
Are you taking any medications?  Yes     No 
Are you pregnant, or is it possible that you may be pregnant? Yes     No 
Does anyone in your family have epilepsy?   Yes     No 
Do you need further explanation of TMS and its associated risks? Yes     No 
If you answered yes to any of the above, please provide details (use reverse if necessary): 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
† For use with single-pulse TMS, paired-pulse TMS, or repetitive TMS. 
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APPENDIX E 
Deakin University Medical Questionnaire 
Responses to this questionnaire will be kept strictly confidential. The responses from this 
questionnaire will provide the investigators with appropriate information to establish suitability 
of your participation in this study. Anyone who is currently carrying a musculo-skeletal injury 
or has a history of past, serious musculo-skeletal injuries, if they have epilepsy, are pregnant or 
have a cardiac pacemaker may be excluded from the study for health and safety reasons. 
NAME: ………………………………………………………………       GENDER:   M / F 
BODY MASS: …………. (kg) HEIGHT: ……….. (cm)  AGE: ……. (yrs) 
Are you currently undertaking any form of regular exercise?   YES NO 
If yes, briefly describe the type and amount (i.e frequency, duration) of exercise you perform: 
1. Are you a smoker? YES NO 
2. Has a medical professional ever told you that you:
2.1. are overweight? YES NO UNKNOWN 
2.2. have high blood pressure?  YES NO UNKNOWN 
2.3. have a heart condition or heart murmur?  YES NO UNKNOWN 
2.4. have asthma or a respiratory condition? YES NO UNKNOWN 
2.5. have diabetes? YES NO UNKNOWN 
2.6. have a bleeding disorder (e.g. haemophilia)? YES NO UNKNOWN 
3. Have you ever had:
3.1. chest pain, discomfort, tightness or heaviness? YES NO UNKNOWN 
3.2. shortness of breath out of proportion to
       exercise undertaken? YES NO UNKNOWN 
3.3. heart palpitations (sensation of abnormally fast 
       and/or irregular heart beat)? YES NO UNKNOWN 
3.4. episodes of fainting, collapse 
       or loss of consciousness? YES NO UNKNOWN 
3.5. abnormal bleeding or bruising? YES NO UNKNOWN 
3.6. gastrointestinal problems?  YES NO UNKNOWN 
4. Do you have a family history of cardiovascular disease?
(eg. heart attack, chest pain/angina, stroke) YES NO UNKNOWN 
If YES, please elaborate:
5. Do you have a family history of diabetes? YES NO UNKNOWN 
If YES, please elaborate:
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6. Have you ever suffered any musculoskeletal injury? YES NO UNKNOWN 
If YES, please elaborate:
7. Have you ever experienced difficulty swallowing YES NO UNKNOWN 
or any other gastrointestinal problem?
If YES, please elaborate:
8. Do you have any allergies? (including to medications) YES NO UNKNOWN 
If YES, please elaborate:
9. Are you currently on any medication? YES NO 
If YES, please list:
10. Are you currently taking anabolic steroids or any
other performance-enhancing agents? YES NO 
11. Is there any other reason which you know of that
would prevent you from undertaking the proposed
exercise and other tests? YES NO 
I believe the information I have provided to be true and correct. 
SIGNED: ……………………………………………..DATE: ………………….. 
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APPENDIX F 
Mini-Mental State Examination (MMSE) 
This test will be used to determine eligibility to participate, participants will be screened 
upfront. 
Maximum 
Score 
Patient’s 
Score 
Questions 
5 “What is the year? Season? Date? Day? Month?” 
5 “Can you name the Country? City? Suburb?” 
3 “I’m going to read out the name of three things to you. 
Man. Ball. Car. 
Please can you name all three of them.” 
Name the three unrelated objects clearly and slowly, then ask the 
person to name all three of them. Repeat them until the 
participant learns all of them, if possible.  
5 “Spell WORLD backwards.” (D-L-R-O-W) 
3 “Earlier I told you the names of three things. Can you tell me 
what those were?” 
1 “Repeat the phrase: ‘No ifs, ands, or buts.’” 
3 “Make up and write a sentence about anything.” (This sentence 
must contain a noun and a verb.) 
25 TOTAL 
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APPENDIX G 
PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
TO:  Participant and carer/guardian 
Plain Language Statement 
Date: 7th January 2015 
Full Project Title: Concurrent strength training and transcranial stimulation to improve gait 
and balance in idiopathic Parkinson’s disease. 
Principal Researcher: Dr Wei-Peng Teo 
Associate Researcher(s): Dr Timo Rantalainen, Dr Liam Johnson, Dr Makii Muthalib, Dr 
Dawson Kidgell, Dr Ashlee Hendy, Dr Michele Callisaya, A.Prof Peter Enticott. 
Student Researcher: Mr Alex Tillman 
You have received this document because you may be eligible to take part in a research 
project investigating new treatments for Parkinson’s disease. Thank you for expressing 
interest in this research project and contacting our research team. It is important that you 
read this document carefully, as it describes the purpose, procedures, risks, benefits, and 
precautions associated with participation in this study. Knowing what is involved will help 
you decide if you want to take part in the research. Please feel free to contact the research 
team if you have any questions regarding the following information. You may also find it 
beneficial to discuss this information with a family member or friend before you make your 
decision.  
1. Background and Purpose:
Parkinson’s disease progressive neurological condition that affects approximately 80,000 
Australians, causing symptoms such as slowness and difficulty initiating movement, postural 
instability, tremor and muscle rigidity. These symptoms are caused by a loss of dopamine in 
the brain, which is commonly treated with medications. At present, medications used to 
treat Parkinson’s can produce unwanted side effects, and tolerance to medications can 
reduce their effectiveness over time. Furthermore, difficulties with walking and balance are 
resistant to medications, with the risk and incidence of falls particularly high among people 
with Parkinson’s disease. As a result, researchers are constantly seeking to find additional 
treatments that may be beneficial at treating symptoms when used alongside regular 
medications. This study has been designed to assess the combination of two popular 
complementary treatments: 1) strength training, and 2) a form of non-invasive brain 
stimulation called ‘tDCS’. Increased muscle strength from strength training has been shown 
to improve balance and walking in people with Parkinson’s disease, which may reduce the 
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risk of falls. Brain stimulation with tDCS has been shown to make the brain more receptive 
to learning and training, which may further enhance the benefits of strength training. While 
both strength training and tDCS have been shown to reduce symptoms in people 
Parkinson’s disease, this study is the first to test the benefits of combining the treatments. 
2. The role of the Participant:
Participation in this study will involve a series of sessions at Deakin University aimed at 
improving brain function, movement and quality of life of people with Parkinson’s disease. 
The study will run for 9 weeks in total, with 18 training sessions (45-60 mins each), and 5 
testing sessions (3 hours each). All sessions will be guided by a researcher.  
Training sessions: 
Participants will be required to attend strength training sessions 3 times per week, on non-
consecutive days, for 6 weeks (18 training sessions in total). The training will take place at 
the Deakin University in Burwood, which contains a weight training gym. The sessions will 
be run by a member of the research team and you will be guided and assisted as required. 
Strength training exercises are aimed at the lower body, and will include leg press, leg 
extensions, hamstring curls and seated calf raises, all performed on fixed gym equipment 
(weight machines). You will perform 3 sets of 6-8 repetitions of each exercise, with the 
machine weight set at 80% of your maximum. During the strength training, you may receive 
tDCS via a hand held, battery operated device during training sessions. The current is 
delivered through damp sponge-like electrodes fastened to your head as shown in Figure 1. 
Figure 1. tDCS 
The tDCS is painless, and often cannot be felt by the participant, but it may cause some mild 
itching or tingling on the skin under the electrodes. Some participants will receive sham-
stimulation in order to rule out a placebo effect. If you are allocated to the sham group, you 
will wear the tDCS unit, but the current will not be active during training. Neither you nor 
the researcher will know if the tDCS unit is active until after you have completed the study 
in full. Some participants will act as controls, and will not be required to participate in 
training or receive tDCS. If you are a control participant, you will be given the option to 
receive the full treatment (6 weeks of strength training with active tDCS) at no cost to you, 
after you complete your role as a control participant. 
Testing sessions: 
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All participants will be required to attend testing sessions, which will help determine any 
improvements that occur from the study. You will complete two testing sessions before 
beginning the exercise training program (week 1), one session during the program (week 3) 
and two sessions after completing the program (week 6 and 9). Each testing session will 
take approximately 3 hours in total. The first testing session will need to be performed both 
with and without some of the medications that you may currently be taking. This will involve 
you delaying your morning dose of medication before arriving at Deakin University. You will 
be asked to bring your medication with you, and consume your morning dose after your 
session is completed. All other testing and training sessions will be performed whilst taking 
you medication as normal. During each testing session, you will perform the following tests: 
Transcranial Magnetic Stimulation (or TMS) will be used to assess your brain function, and 
will provide information about how effectively your brain activates you muscles. This 
procedure involves the use of a magnetic field to induce current in the brain, which in turn 
causes a brief muscle twitch. When receiving TMS, the researcher will place a magnetic coil 
above the region of your brain that produced muscle contractions. When the researcher 
discharges the coil, you will hear a ‘click’ and may feel a light tap on your scalp underneath 
the coil. This will cause an involuntary muscle contraction, or twitch, which is recorded by 
small electrodes placed on the skin. A signal depicting the muscle contraction will appear on 
the computer screen, allowing the researcher to determine any changes in your muscle 
activation levels. Figure 2 shows TMS being delivered. 
Figure 2. A participant receiving TMS 
Strength testing will be performed on the weight machines in the gym, where you will be 
required to perform each exercise (leg press, leg extension, hamstring curl and seated calf 
raise) with the heaviest weight possible. You will start by practicing the exercise with a 
moderate weight, with more weight being gradually added until you can no longer perform 
the exercise. All exercises have been chosen carefully to minimize any risk of falling or injury 
whilst being performed.  
Gait (walking) and balance testing will be performed in the Biomechanics laboratory. The 
timed-up-and-go test will require you to stand up from a seated position and walk short 
distance while a researcher times you. The 2 minute walking test will require you to walk 
laps of a 25 meter walkway for two minutes while a researcher records your speed and 
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distance. The walking test is repeated twice, once while just walking at your preferred pace, 
and once while walking, and saying words aloud beginning with a given letter (such as words 
beginning with the letter ‘U’) while walking at your preferred pace. Your gait characteristics 
will be recorded from the walking tests by a small light-weight accelerometer we will ask 
you to wear on your hip, and with an instrumented 5 meter long mat placed mid-way 
through the 25 meter walkway. The balance test will require you to stand on a force 
measuring plate while you perform several tasks, such as standing on one leg, or standing 
with your eyes closed. 
Functional near-infrared spectroscopy will be used to measure changes in blood flow in 
various areas of the brain while you perform the walking and balance tests. You will be 
asked to wear a small device, taped to your forehead, which emits and records light from 
your scalp. This procedure is safe, and you will not feel any sensations from the light 
emitted by device. 
After you have completed the study, you will be asked to complete an online survey on how 
you felt after receiving tDCS and TMS. The information gathered from this question will help 
us to assess the effectiveness of stimulation and record any side-effects that you may have 
experienced.  
3. Potential risks and benefits:
There are no foreseeable medical risks to participation in this project. Although rare, some 
participants may experience discomforts such as local pain on the scalp musculature or a 
headache following non-invasive brain stimulation (tDCS and TMS). The strength training 
program and strength testing may cause mild muscle soreness and stiffness, however this is 
a normal response to strength training and in most cases will subside within 1-2 days. All 
testing and training procedures have been chosen carefully to minimize any risk of falling or 
injury, and experienced researchers will be present at all times to ensure the highest level of 
safety. You will have access to medical center on site at Deakin University in the unlikely 
event of any adverse occurrences during the study.  
Participation in this project is likely to provide several benefits to both the individual and the 
wider community. It is anticipated that participants will experience improved performance 
in strength, walking and balance following the strength training program, which may be 
further enhanced in participants receiving active tDCS. These improvements may reduce the 
risk of falls and have a positive impact on quality of life. Furthermore, the results of this 
study will contribute to wider scientific knowledge in regards to the optimal treatment for 
Parkinson’s disease and other movement related diseases. 
4. Privacy, confidentiality and disclosure of information:
Any personal information provided by you to the researchers involved with this project will 
remain confidential. It is likely that the results of this study will be published in scientific 
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journals and discussed at national or international conferences. In such circumstances your 
identity will not be disclosed. In all cases, information will be provided in such a way that 
you cannot be identified. In addition, any information collected will be coded and de-
identified, and stored securely in electronic format where only the researchers will have 
access to the data. 
5. Results of the study
Upon completion of the project, it is anticipated that the results will be submitted for 
potential peer-review and scientific journal publication. The results may also be presented 
orally to a scientific meeting in Australia or internationally. Participants that would like 
copies of published material arising from the project may request this from the principle 
researcher at the conclusion of the project.  
6. How the study will be monitored
Although unlikely, it is possible that new information about the risks and benefits of the 
treatments may become known while you are participating in the project. If this occurs, you 
will be told about this new information immediately. You will be monitored and assisted by 
researchers during each testing and training session. If it appears for any reason that you or 
the research staff are at risk by your continuing participation in the study, the person(s) 
supervising the research will stop your participation. In all cases, you will be offered all 
available care to suit your needs and medical condition. 
7. Costs and payments associated with the research
Participation in this research is free. All costs, including reimbursement for transportation 
costs, will be covered by Deakin University. You will not be paid for participation in this 
research. 
8. Participation is voluntary
Participation in this research project is voluntary. If you do not wish to take part you are 
not obliged to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage. If you choose to withdraw, any information 
obtained from you to date will not be used and will be destroyed. Your decision whether to 
take part or not to take part, or to take part and then withdraw, will not affect your 
relationship with Deakin University or any members of the research team. 
9. Complaints
If you have any complaints about any aspect of the project, the way it is being conducted or 
any questions about your rights as a research participant, then you may contact:   
The Manager, Ethics and Biosafety, Deakin University, 221 Burwood Highway, Burwood 
Victoria 3125, Telephone: 9251 7129, research-ethics@deakin.edu.au 
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Please quote project number: 2015-014. 
10. Further information
If you require further information, wish to withdraw your participation or if you have any 
problems concerning this project (for example, any side effects), you can contact the 
research team at any time.  
Principle Researcher: 
Dr Wei-Peng Teo 
School of Exercise and Nutrition Sciences 
Deakin University 
221 Burwood Hwy, Burwood, VIC 3125 
Telephone: +61 3 9244 5229 
Email: weipeng.teo@deakin.edu.au 
Associate Researcher: 
Dr Timo Rantalainen 
School of Exercise and Nutrition Sciences 
Deakin University 
221 Burwood Hwy, Burwood, VIC 3125 
Telephone: +61 3 9251 7256 
Email: t.rantalainen@deakin.edu.au 
Associate Researcher: 
Dr Ashlee Hendy 
School of Exercise and Nutrition Sciences 
Deakin University 
221 Burwood Hwy, Burwood, VIC 3125 
Telephone: +61 3 9244 6221 
Email: a.hendy@deakin.edu.au 
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 PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
TO:  Participant 
Consent Form 
Date: 7th January 2015 
Full Project Title: Concurrent strength training and transcranial stimulation to improve gait 
and balance in idiopathic Parkinson’s disease. 
Reference Number: 2015-014 
I have read, and I understand the attached Plain Language Statement. 
I freely agree to participate in this project according to the conditions in the Plain Language 
Statement.  
I have been given a copy of the Plain Language Statement and Consent Form to keep. 
The researcher has agreed not to reveal my identity and personal details, including where 
information about this project is published, or presented in any public form.   
Participant’s Name (printed) …………………………………………………………………… 
Signature ……………………………………………………… Date  ………………………… 
Please mail or email this form to: 
Dr Wei-Peng Teo 
School of Exercise and Nutrition Science 
Deakin University 
221 Burwood Hwy 
Burwood, Victoria, 3125 
weipeng.teo@deakin.edu.au 
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PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
TO:  Carer of participant 
Third Party Consent Form 
(To be used by parents/guardians of minor children, or carers/guardians consenting on 
behalf of adult participants who do not have the capacity to give informed consent) 
Date: 7th January 2015 
Full Project Title: Concurrent strength training and transcranial stimulation to improve gait 
and balance in idiopathic Parkinson’s disease. 
Reference Number: 2015-014 
I have read, and I understand the attached Plain Language Statement. 
I give my permission for ……………………………………………………(name of participant) 
to participate in this project according to the conditions in the Plain Language Statement. 
I have been given a copy of Plain Language Statement and Consent Form to keep. 
The researcher has agreed not to reveal my identity and personal details or the identity and 
personal details of the person for whom I am providing consent, including where 
information about this project is published, or presented in any public form.   
Participant’s Name (printed) …………………………………………………… 
Name of Person giving Consent (printed) …………………………………………………… 
Relationship to Participant: ……………………………………………………… 
Signature ……………………………………………………… Date  ………………………… 
Please mail or email this form to: 
Dr Wei-Peng Teo 
School of Exercise and Nutrition Science 
Deakin University 
221 Burwood Hwy 
Burwood, Victoria, 3125 Email: weipeng.teo@deakin.edu.au 
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PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
TO:  Participant 
Withdrawal of Consent Form 
(To be used for participants who wish to withdraw from the project) 
Date: 7th January 2015 
Full Project Title: Concurrent strength training and transcranial stimulation to improve gait 
and balance in idiopathic Parkinson’s disease. 
Reference Number: 2015-014 
I hereby wish to WITHDRAW my consent to participate in the above research project and understand that such 
withdrawal WILL NOT jeopardise my relationship with Deakin University. 
Participant’s Name (printed) ……………………………………………………. 
Signature ………………………………………………………………. Date …………………… 
Please mail or email this form to: 
Dr Wei-Peng Teo 
School of Exercise and Nutrition Science 
Deakin University 
221 Burwood Hwy 
Burwood, Victoria, 3125 
Email: weipeng.teo@deakin.edu.au 
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APPENDIX H 
Progressive resistance training intervention: Leg Press 
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Progressive resistance training intervention: Squats 
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Progressive resistance training intervention: Toe lifts 
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Progressive resistance training intervention: Calf raises 
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APPENDIX I 
Balance-specific training intervention: Tandem walk 
150 
Balance-specific training intervention: Tandem stance with progression 
151 
Balance-specific training intervention: One leg stance with progression 
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Balance-specific training intervention: Hurdle walk 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2156 C.G. GOETZ ET AL.
APPENDIX J 
153 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2157MDS-UPDRS: CLINIMETRIC ASSESSMENT
154 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2158 C.G. GOETZ ET AL.
155 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2159MDS-UPDRS: CLINIMETRIC ASSESSMENT
156 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2160 C.G. GOETZ ET AL.
157 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2161MDS-UPDRS: CLINIMETRIC ASSESSMENT
158
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2162 C.G. GOETZ ET AL.
159 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2163MDS-UPDRS: CLINIMETRIC ASSESSMENT
160 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2164 C.G. GOETZ ET AL.
161 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2165MDS-UPDRS: CLINIMETRIC ASSESSMENT
162 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2166 C.G. GOETZ ET AL.
163 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2167MDS-UPDRS: CLINIMETRIC ASSESSMENT
164 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2168 C.G. GOETZ ET AL.
165 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2169MDS-UPDRS: CLINIMETRIC ASSESSMENT
166 
Copyright  2008 Movement Disorder Society. All rights reserved.
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement Disorder Society.
2170 C.G. GOETZ ET AL.
167 
Berg Balance Scale 
	
			

		


	






		


	











	
	

	
	
			




	
		



 !

"
	

 !"	
	
		
	
	



 #	$

$
$
	$$ %	
		

   %"&'

	
 ("
	$

'"!)'*
			



)!*		

	+%,

	
 ! "%,+			
& "!'+		
'-&'+		
(
.
	






&

APPENDIX K 
168 


/01111111111111111111111111111111111 201111111111111111111
3
011111111111111111111111111111111 #01111111111111111111
45246#78/ 68#4'"!



 11111111



 11111111
Sitting unsupported ________ 



 11111111

 11111111


	 11111111


 11111111
#
 11111111
#
9	 11111111


	
  11111111


:,' 11111111
7	
	

	  11111111





  11111111




 11111111
	 11111111
;4/4#(3/#<68/
7	

=


>

$	
	
	

$9



7	

0
• 



• 9?



• 9
@
	
@

9	



	
	

	

	979
		
	
	




4



$
	

&$%$
 '
6

	
	4
	A &
169 


/;8(/2/;
/#<68/07	



! 	



	B


	
: 	



	


& 	


	
  

	
	B
' 
@	

(/2/;</<778#42
/#<68/07	

	


! 	
	&

: 	
&


& 	
:'


  
	
:'


' 
	
:'


9	
&

$		


7A!
/;>C(6D</<778#42<E44<778#428/E388#8#8/(883
/#<68/07		&

! 		
	&

: 	&



& 		:'

  	 '

' 
	 '

(/2/;8/;
/#<68/07	

! 	
	

: 
	



& 	

	

  


	

		

' 

#(/E4#
/#<68/0(

(9




F




! 	
	


: 	
	



& 	
	

=

  



' 
	
(/2/;</<778#42>C4F463842
/#<68/07		

		 '

! 	
 '
	
: 	
 '


& 	
:

  
		:
	
' 
			

(/2/;</<778#42>CE448;4C4#
/#<68/07	

	


! 		


	

 
	
: 		


	

 


& 		


	
		:'

  
	

	
 %

' 
	



		 %

170 



G
#4(6C/;E8#>(#2>C8<#46C42(#5>C34(/2/;
/#<68/03H'


4@
		



H'E
	
		



	9
	

>
	$9





! 


	&% '

: 
 &%

& 
%&

  


' 		
	
=@
	
76D<78I46E#85C4E388#E#85((/2/;788/
/#<68/07=	$


! 			
	
: 		


& 
	&"% "&
	
	



	
  
	


	

' 
	=
	
	
		

<#//;8388D4C/28J4#34E(/2#;CC8<324#>C34(/2/;
/#<68/0
		
		#4@

9
		
9


! 	

		
: 	


		
& 

	

	

  





' 
	
	
		

<#/:,'24;#44
/#<68/0
		

			7

			


! 	
:,'	
!
	
: 	
:,'	

	!
	
& 	
:,'			
  
	
	

' 

	


73(64(34#/(4E888/478#883>C34(/2/;</<778#42
/#<68/07		
	
=	6


	=	
! 	



	
	
	.
&'

: 	



	
	.
K&'

& 		!

  		K&

	
' 

		
=
	
(/2/;</<778#428/4E88/E#8/
/#<68/02458/#(48<I467	
	

	

	
	

$
	
:
$	
	@	


	@
9?
	
! 		



	
	:'

: 		


	
	:'

& 			


	
	:'

  
	
	 %

' 		
	



(/2/;8/8/434;
/#<68/0


		

	


! 			


	
	K '

: 			


	
	%" '

& 			


	
	L:

  		
		:






	
' 
	

		
 8(368#45@+%,
171 
172 
APPENDIX L 
Strength assessment: Leg press 1-RM of the Ham 
173 
Strength assessment: Leg extension 1-RM of the Quad 
174 
Strength assessment: Plantarflexion 1-RM of the Gas 
175 
Strength assessment: Dorsiflexion 1-RM of the TA 
